

Committee on Energy and Commerce
U.S. House of Representatives
 Witness Disclosure Requirement - "Truth in Testimony"
 Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Robert L. DuPont, MD		
2. Your Title: President		
3. The Entity(ies) You are Representing: Institute for Behavior and Health, Inc.		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
<p>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</p> <p>The following are related to drug-policy, not drugged driving specifically:</p> <p>2015, 2016, 2017, 2018: Washington/Baltimore High Intensity Drug Trafficking Area – Contract with Institute for Behavior and Health for the Evaluation of Recidivism Rates for Criminal Offenders Discharged from Substance Abuse Treatment Programs Funded by W/B HIDTA</p> <p>2016: Pontifical Academy of Sciences, Vatican City – Travel expenses paid for participation in workshop <i>Narcotics: Problems and Solutions of this Global Issue</i></p>		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____ **Date:** July 9, 2018 _____

CURRICULUM VITAE

NAME, EMAIL, DATE OF BIRTH

Robert L. DuPont, M.D. bobdupont@aol.com
March 25, 1936

Dr. DuPont is a practicing psychiatrist with substantial research and administrative experience who has specialized for more than three decades in the problems of addiction and the anxiety disorders. Dr. DuPont is a Life Fellow of the American Psychiatric Association and the Society of Behavioral Medicine (1985 – 1996), and Distinguished Fellow of the American Society of Addiction Medicine. He is listed in *The Best Doctors in America*.

CURRENT POSITIONS

President
Institute for Behavior and Health, Inc.
6191 Executive Boulevard
Rockville, MD 20852
Phone: (301) 231-9010
Fax: (301) 231-5119
www.ibhinc.org

The Institute for Behavior and Health, Inc. is a non-profit organization dedicated to reducing illegal drug use.

President
DuPont Associates, P.A.
6191 Executive Boulevard
Rockville, MD 20852
Phone: (301) 231-9010

DuPont Associates, P.A. is a clinical and consulting mental health practice.

Clinical Professor of Psychiatry
Georgetown University
School of Medicine
Washington, D.C.

Dr. DuPont teaches medical students and residents in psychiatry.

EDUCATION

June 1963	M.D. Harvard Medical School Boston, Massachusetts
June 1958	B.A. Emory University Atlanta, Georgia

POST-GRADUATE TRAINING

- 1966 – 1968 Clinical Associate
Bethesda, MD
Laboratory of Clinical Sciences
National Institutes of Health
- 1964 – 1966 Psychiatric Resident and Teaching Fellow in Psychiatry
Boston, MA
Massachusetts Mental Health Center
Harvard Medical School
- 1963 – 1964 Medical Intern
Cleveland, OH
MetroHealth Medical Center
(formerly Cleveland Metropolitan General Hospital)
Western Reserve Medical School

CHRONOLOGY OF PAST EMPLOYMENT

- 2003 – 2015 Chairman
Prescription Drug Research Center, LLC
Fairfax, VA
- 1982 – 2015 Executive Vice President
Bensinger, DuPont & Associates
Chicago, IL
- 1981 – 1984 Founding President
Anxiety Disorders Association of America
Rockville, MD
- 1980 – 1984 President
American Council for Drug Education
Rockville, MD
- 1978 – 1989 Founding President
Center for Behavioral Medicine
Rockville, MD
- 1978 – 1979 Family Psychiatrist, appearing regularly on “Good Morning
America,” ABC-TV
New York, NY

1975 – 1977	Chair Cabinet Committee on Demand Reduction The White House Executive Office of the President Washington, DC
1974 (2 months)	Acting Administrator Alcohol, Drug Abuse and Mental Health Administration U.S. Department of Health, Education and Welfare Rockville, MD
1973 – 1978	First Director National Institute on Drug Abuse U.S. Department of Health, Education and Welfare Rockville, MD
1973 – 1975	Director Special Action Office for Drug Abuse Prevention (Drug Czar) The White House Executive Office of the President Washington, DC
1970 – 1973	Founding Administrator Narcotics Treatment Administration Department of Human Resources Government of the District of Columbia Washington, DC
1968 – 1970	Research Psychiatrist and Associate Director for Community Services District of Columbia Department of Corrections Washington, DC
1965 – 1966 (part-time)	Senior Psychiatrist Massachusetts Department of Corrections Norfolk Prison Norfolk, MA
1961 (3 months)	Research Assistant Tuberculosis Laboratory Communicable Disease Center Atlanta, GA
1959 (3 months)	Epidemiology Trainee California Department of Public Health Berkeley, CA

CONSULTANTSHIPS, BOARD MEMBERSHIPS AND OTHER ACTIVITIES

2017 – Present	Senior Adviser Americans for Responsible Drug Policy
2015 – Present	Consultant Prescription Drug Research Center
2013	Chair ASAM Drug Testing White Paper Writing Committee American Society of Addiction Medicine
2013 – Present	Member National Advisory Board National Rx Drug Abuse & Heroin Summit
2012 – Present	Non-Resident Senior Fellow Institute for Drug Policy University of Florida College of Medicine
2012 – Present	Member Board of Advisors Shatterproof
2012 – 2013	Member Board of Advisors We Saves Lives
2012	Co-Chair ASAM Writing Committee to Develop a Response to State-Level Proposals to Legalize Marijuana American Society of Addiction Medicine
2010 – Present	Member Board of Directors Oxford House
2010 – Present	Member National Association of Drug Diversion Investigators
2010 – Present	Member Board of Directors The Mentor Foundation USA
2010 – 2011	Co-Chair President’s Action Committee on Medical Marijuana

American Society of Addiction Medicine

2009 – Present Board Member Representing North America
 Leader of Americas Section
 World Federation Against Drugs

2009 – 2013 Member
 Advisory Committee
 National Partnership on Alcohol Misuse and Crime

2009 – 2012 Member
 Board of Directors
 National Association of Drug Court Professionals

2006 – 2009 President
 The Kolmac Foundation

1997 – 1999 Member
 Advisory Board
 The Recovery Network, Inc.

1995 – 2004 Member
 Editorial Board of Consultants
Directions in Psychiatry
 The Hatherleigh Company, Ltd.

1995 – 2004 Chair
 Committee on Forensic Addiction Medicine
 American Society of Addiction Medicine

1992 – 1998 Member
 Board of Scientific and Policy Advisors
 American Council on Science and Health (ACSH)

1991 – 1995 Member
 Scientific Advisory Board
 National Anxiety Foundation

1991 – 1994 Member
 Drug Use Forecasting (DUF) Advisory Board
 National Institute of Justice

1990 – 1994 Member
 The Med Chi Alliance Against Drug Abuse
 The Medical and Chirurgical Faculty of Maryland

1989 – 2003	Chairman Scientific Advisory Board Psychomedics Corporation
1989 – 1993	Member Advisory Board National Family Partnership
1988 – 1996	Chairman Scientific Advisory Panel Corporation Against Drug Abuse
1980 – 1993	Member, Advisory Board Parents Council
1980 – 1990	Board of Directors Anxiety Disorders Association of America
1973 – 1987	Chairman World Psychiatric Association Section on Alcohol and Drug Dependence
1978 – Present	Chairman Board of Directors Institute for Behavior and Health, Inc.
1978 – Present	Member Screen Actors Guild-American Federation of Television and Radio Artists
1977 – 1979	Member, Board of Advisors Women’s Work, Inc.
1976 – 1978	Chairman National Advisory Council on Drug Abuse U.S. Department of Health, Education and Welfare
1976 – 1977	Chairman Cabinet Committee on Drug Abuse Prevention, Treatment and Rehabilitation The White House
1974 – 1978	U.S. Delegate to United Nations Commission on Narcotic Drugs

1972 – 1976	Member, Board of Directors Washington Society for the Performing Arts
1972 – 1976	Member, Advisory Committee Washington Junior League
1972 – 1973	Member National Advisory Council on Drug Abuse Prevention A Presidential Appointment
1971 – 1972	Consultant Special Committee on Crime Prevention and Control American Bar Association

FACULTY APPOINTMENTS

1980 – Present	Clinical Professor of Psychiatry Georgetown University School of Medicine
1978 – 1984	Visiting Associate Clinical Professor of Psychiatry Harvard Medical School
1972 – 1981	Associate Clinical Professor of Psychiatry and Behavioral Sciences George Washington University Medical School
1964 – 1966	Teaching Fellow in Psychiatry Harvard Medical School

HONORS

2014	Lifetime Achievement Award Smart Approaches to Marijuana Washington, DC: February 5 th
2012	Lifetime Achievement Award Caron Treatment Centers Washington, DC: September 12 th
2011	Silver Key Award National Council on Alcoholism and Drug Dependence, Inc. Arlington, Virginia: September 9 th
2008	Honorary Interim Director of the ABAM Foundation 2007-2008

- American Board of Medical Specialties
Alexandria, Virginia: April 15th
- 2008 ASAM Award “for outstanding contributions to the growth and vitality of our Society, for thoughtful leadership in the field, and for deep understanding of the art and science of Addiction Medicine”
American Society of Addiction Medicine
Toronto, Canada: April 12th
- 2002 John P. McGovern Compleat Physician Award
Harris County Medical Society
Houston Academy of Medicine: February 1st
- 1992 – Present Listed in *The Best Doctors in America*
- 1999 McGovern Award for Distinguished Lecturer in Family Health and Human Values
University of Houston
College of Humanities, Fine Arts and Communication: October 14th
- 1999 McGovern Centennial Award for Leadership in Communication
University of Texas at Austin
College of Communication: September 16th
- 1999 McGovern Award for Contributions in the Field of Addiction and Society
American Society of Addiction Medicine
New York, NY: May 1st
- 1997 Academic Achievement Award
Substance Abuse Program
Administrators Association
- 1986 National Federation of Parents for Drug-Free Youth Award for Service and Contribution to the National Parent Movement
- 1978 Public Health Service Superior Service Award: Highest award given by the U.S. Public Health Service, presented by the Surgeon General, Julius B. Richmond, M.D.
- 1978 The Alcohol and Drug Problems Association of North America
Annual Award for Outstanding Leadership and Service
- 1978 National Association of State Drug Abuse Coordinators Annual
National Award for Outstanding Contributions to Drug Abuse Prevention

1973 Meritorious Service Award, District of Columbia Government,
presented by Mayor Walter E. Washington

1971 – 1972 Melvin C. Hazen Award to the Outstanding Young Man in the
District of Columbia Government

MEDICAL LICENSES

Maine
Maryland

MILITARY SERVICE

1966 – 1968 Senior Surgeon (Major)
U.S. Public Health Service
National Institutes of Health
Bethesda, MD

PROFESSIONAL SOCIETIES

American Board of Addiction Medicine (Diplomate)
American Medical Association
American Psychiatric Association (Life Fellow)
American Society of Addiction Medicine (Distinguished Fellow)
Washington Psychiatric Society

CERTIFICATION

2009 – Present Certified in Addiction Medicine by the American Board of
Addiction Medicine

1998 – 2013 Certified as Medical Review Officer by the American Society of
Addiction Medicine

1994 – 2004 Diplomat in Psychiatry with Added Qualification in Addiction
Psychiatry American Board of Psychiatry and Neurology

1994 – 1999 Certified as a Medical Review Officer by the Medical Review
Officer Certification Council

1988 – 2009
Recertified 1998

Certified in alcoholism and other drug dependencies through
examination by the American Society of Addiction Medicine

1970 – Present

Diplomat in Psychiatry
American Board of Psychiatry and Neurology

BOOKS & MONOGRAPHS

1. DuPont, R. L., Goldstein, A. & O'Donnel, J. (Eds.). (1978). *Handbook on drug abuse*. Rockville, MD: National Institute on Drug Abuse.
2. DuPont, R. L. (Ed.). (1982). *Phobia: A comprehensive summary of modern treatments*. New York: Brunner/Mazel.
3. Weissman, J. C. & DuPont, R. L. (1982). *Criminal justice and drugs: The unresolved connection*. Port Washington, NY: Kennikat Press.
4. DuPont, R. L. (1984). *Getting tough on gateway drugs: A guide for the family*. Washington, D.C.: American Psychiatric Press.
5. DuPont, R. L. (1986). *Phobias and panic: A physician's guide to modern treatments*. Rockville, MD: Phobia Society of America.
6. DuPont, R. L. (1986). *Benzodiazepines: The social issues*. Rockville, MD: The Institute for Behavior and Health, Inc.
7. DuPont, R. L. (Ed.). (1987). *Drug abuse research: An agenda for action*. Rockville, MD: Institute for Behavior and Health, Inc.
8. DuPont, R. L. (Ed.). (1989). *Stopping alcohol and other drug use before it starts: The future of drug abuse prevention* (OSAP Prevention Monograph 1). Rockville, MD: Office of Substance Abuse Prevention.
9. DuPont, R. L. (1990). *Benzodiazepine therapy in insomnia and anxiety*. Chicago: Pragmaton.
10. DuPont, R. L. (Ed.). (1991). *Crack cocaine: A challenge for prevention*. (OSAP Prevention Monograph-9). Rockville, MD: Office of Substance Abuse Prevention.
11. DuPont, R. L. & McGovern, J. P. (1994). *A bridge to recovery – An introduction to 12-step programs*. Washington, D.C.: American Psychiatric Press.
12. DuPont, R. L. (1997). *The selfish brain: Learning from addiction*. Washington, D.C.: American Psychiatric Press.

13. DuPont, R. L., Spencer, E. D. & DuPont, C. M. (1998). *The anxiety cure: An eight-step program for getting well*. New York: John Wiley & Sons.
14. DuPont, R. L. (2000). *The selfish brain: Learning from addiction (Revised and updated)*. Center City, MN: Hazelden.
15. Spencer, E. D., DuPont, R. L. & DuPont, C. M. (2003). *The anxiety cure for kids: A guide for parents*. Hoboken, NJ: Wiley.
16. DuPont R. L., Newel, R. & Brethen, P. (2005). *Drug testing in drug abuse treatment*. Center City, MN: Hazelden.
17. DuPont, R. L. & Brady L. A. (2005). *Drug testing in schools: Guidelines for effective use*. Center City, MN: Hazelden.
18. DuPont, R. L., Mieczkowski, T. & Newel, R. (2005). *Drug testing in the criminal justice system*. Center City, MN: Hazelden.
19. Spencer, E. D., DuPont, R. L. & DuPont, C. M. (2013). *The anxiety cure for kids: A guide for parents and children* (2nd ed). Nashville, TN: Turner Publishing Co.

PROFESSIONAL PUBLICATIONS

1. DuPont, R. L. & Grunebaum, H. U. (1968). Willing victims: The husbands of paranoid women. *American Journal of Psychiatry*, 125, 150-159.
2. DuPont, R. L. (1969). An imposter in psychotherapy. *Psychiatric Opinion*, 6, 38-43.
3. DuPont, R. L. (1970). Narcotics treatment as crime reduction and human resources strategy. *Trends*, 1(2), 1, 4-5, 7-8.
4. Brown, B. S., Markman, E. M. & DuPont, R. L. (1970). Released offenders' perceptions of community and institution. *Corrective Psychiatry and Journal of Social Therapy*, 16, 88-96.
5. DuPont, R. L. (1970). The imposter and his mother. *Journal of Nervous and Mental Disease*, 150, 444-448.
6. Brown, B. S., DuPont, R. L. Kozel, N. J. & Spevacek, J. K. (1971). Staff and client views of the role of the correctional client: Conflict and its implications for treatment. *Social Psychiatry*, 6, 83-88.
7. Brown, B. S., DuPont, R. L. Kozel, N. J. & Spevacek, J. K. (1971). Staff conceptions of inmate characteristics: A comparison of treatment and custodial staffs at two differing institutions. *Criminology*, 9, 316-329.

8. DuPont, R. L. (1971). How corrections can beat the high cost of heroin addiction. *Federal Probation*, 35, 43-50.
9. DuPont, R. L. (1971). Profile of a heroin-addiction epidemic. *New England Journal of Medicine*, 285, 320-324.
10. DuPont, R. L. (1971). Urban crime and the rapid development of a large heroin addiction treatment program. *Proceedings of the Third National Conference on Methadone Treatment* (pp 115-120). New York.
11. DuPont, R. L. (1971). Veteran heroin addicts in Washington: A preliminary report. *Medical Annals of the District of Columbia*, 40, 521-523.
12. DuPont, R. L., Grunebaum, H. U. & Ryder, R. G. (1971). An unexpected result of psychosis in marriage. *American Journal of Psychiatry*, 128, 735-739.
13. DuPont, R. L. & Katon, R. N. (1971). Development of a heroin addiction treatment program: Effect on urban crime. *Journal of the American Medical Association*, 216, 1320-1324.
14. DuPont, R. L. & Katon, R. N. (1971). Physicians and the heroin addiction epidemic. *Modern Medicine*, 39, 123-139.
15. Bass, U. F., Brown, B. S. & DuPont, R. L. (1972). The use of heroin by an offender population: A report over time. *Corrective Psychiatry and Journal of Social Therapy*, 18, 24-30.
16. Brown, B. S., DuPont, R. L., Bass, U. F., Glendinning, S. T., Kozel, N. J. & Meyers, M.B. (1972). Impact of a multimodality treatment program for heroin addicts. *Comprehensive Psychiatry*, 13, 391-397.
17. Brown, B.S., DuPont, R. L. & Glendinning, S. T. (1972). Narcotics treatment and behavioral change. *Proceedings of the Fourth National Conference on Methadone Treatment* (pp. 163-168). Washington, DC: Narcotics Treatment Administration.
18. Brown, B. S., DuPont, R. L. & Nolfi, R. J. (1972). A reexamination of the use of illicit drugs by methadone maintenance patients. *Proceedings of the Fourth National Conference on Methadone Treatment* (pp. 469-472). Washington, DC: Narcotics Treatment Administration.
19. DuPont, R. L. (1972). Heroin addiction treatment and crime reduction. *American Journal of Psychiatry*, 128, 856-860.
20. DuPont, R. L. (1972, November). How to identify heroin problem. *Justice*, 10-12.
21. DuPont, R. L. (1972). The District of Columbia experience treating heroin addicts. *Public Management*, 54, 7-9.

22. DuPont, R. L. (1972). Treating heroin addicts in Washington. *Delaware Medical Journal*, 44, 35-37.
23. DuPont, R. L. (1972). Trying to treat all the heroin addicts in a community. *Proceedings of the Fourth National Conference on Methadone Treatment* (pp. 77-80). Washington, DC: Narcotics Treatment Administration.
24. Katon, R. N., DuPont, R. L. & Rubenstein, R. M. (1972). Methadone detoxification of heroin addicts. *Proceedings of the Fourth National Conference on Methadone Treatment* (pp. 181-186). Washington, DC: Narcotics Treatment Administration.
25. Kozel, N. J., DuPont, R. L. & Brown, B. S. (1972). Narcotics and crime: A study of narcotic involvement in an offender population. *International Journal of the Addictions*, 7, 443-450.
26. Sherwood, G. K., McGinnis, M. H., Katon, R. N., DuPont, R. L. & Webster, J. B. (1972). Negative direct Coombs' tests in narcotic addicts receiving maintenance doses of methadone. *Blood*, 40, 902-904.
27. Webster, J. B., Katon, R. N. & DuPont, R. L. (1972). Multiphasic screening of inner-city heroin users revealing some of the social, physical and chemical characteristics of this population. *Proceedings of the Fourth National Conference on Methadone Treatment* (pp. 511-513). Washington, DC: Narcotics Treatment Administration.
28. Amos, E. D., DuPont, R. L. & Lau, J. P. (1973). The management of large multimodality, multiclinic drug treatment programs and management information systems. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 875-888). Washington, DC: Narcotics Treatment Administration.
29. Brown, B. S., DuPont, R. L., Bass, U. F., Brewster, G. W., Glendinning, S. T., Kozel, N. J. & Meyers, M. B. (1973). Impact of a large-scale narcotics treatment program: A six month experience. *International Journal of the Addictions*, 8, 49-57.
30. Brown, B. S., DuPont, R. L. & Kozel, N. J. (1973). Heroin addiction in the city of Washington. *Drug Forum*, 2, 187-190.
31. Brown, B. S., Kozel, N. J., Meyers, M. B. & DuPont, R. L. (1973). Use of alcohol by addict and nonaddict populations. *American Journal of Psychiatry*, 130, 599-601.
32. Chabalko, J., LaRosa, J. & DuPont, R. L. (1973). Death of methadone users in the District of Columbia. *International Journal of the Addictions*, 8, 897-908.
33. Cochran, D. A. & DuPont, R. L. (1973). A statistical history of the Narcotics Treatment Administration. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 889-898). Washington, DC: Narcotics Treatment Administration.

34. DuPont, R. L. (1973). Coming to grips with an urban heroin addiction epidemic. *Journal of the American Medical Association*, 223, 46-48.
35. DuPont, R. L. (1973). Where does one run when he's already in the promised land? *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 1394-1402). Washington, DC: Narcotics Treatment Administration.
36. DuPont, R. L. & Greene, M. H. (1973). The decline of heroin addiction in the District of Columbia. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 1474-1483). Washington, DC: Narcotics Treatment Administration.
37. DuPont, R. L. & Greene, M. H. (1973). The dynamics of a heroin addiction epidemic. *Science*, 181, 716-722.
38. DuPont, R. L. & Greene, M. H. (1973). Patterns of heroin addiction in the District of Columbia. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 786-793). Washington, DC: Narcotics Treatment Administration.
39. DuPont, R. L. & Piemme, T. E. (1973). Estimation of the number of narcotic addicts in an urban area. *Medical Annals of the District of Columbia*, 42, 323-326.
40. Greene, M. H. & DuPont, R. L. (1973). Amphetamines in the District of Columbia: I. Identification and resolution of an abuse epidemic. *Journal of the American Medical Association*, 226, 1437-1449.
41. Greene, M. H. & DuPont, R. L. (1973). An outbreak of intravenous amphetamine abuse in heroin addicts. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 776-785). Washington, DC: Narcotics Treatment Administration.
42. Greene, M. H. & DuPont, R. L. (1973). Medical complications associated with the use of methadone: Methadone related mortality. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 811-822). Washington, DC: Narcotics Treatment Administration.
43. Greene, M. H., Luke, J. L. & DuPont, R. L. (1973). Acute opiate overdose: A preliminary report on mechanisms of death. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 330-334). Washington, DC: Narcotics Treatment Administration.
44. Greene, M. H., Rubenstein, R. M. & DuPont, R. L. (1973). Amphetamines in the District of Columbia: II. Patterns of abuse in an arrestee population. *Archives of General Psychiatry*, 29, 773-776.
45. Lloyd, R. A., Katon, R. N., DuPont, R. L. & Rubenstein, R. M. (1973). Detoxification: What makes the difference? *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 275-283). Washington, DC: Narcotics Treatment Administration.

46. Perpich, J., DuPont, R. L. & Brown, B. S. (1973). Criminal justice and voluntary patients in treatment for heroin addiction. *Proceedings of the Fifth National Conference on Methadone Treatment* (pp. 78-84). Washington, DC: Narcotics Treatment Administration.
47. Wilson, J. Q. & DuPont, R. L. (1973, October). The sick sixties. *Atlantic Monthly*, 91-98.
48. DuPont, R. L. (1974, January 25). Drug-abuse education a failure so far. *Los Angeles Times*.
49. DuPont, R. L. (1974). The evolving federal substance abuse organization. *American Journal of Drugs and Alcohol Abuse*, 1, 1-9.
50. DuPont, R. L. (1974). The future of the federal drug abuse program. *Committee on Problems of Drug Dependence: Report of the 36th Annual Scientific Meeting, National Academy of Sciences, National Academy of Engineering, National Research Council* (pp. 42-47). Mexico City, Mexico.
51. DuPont, R. L. (1974). The rise and fall of heroin addiction. *Natural History*, 83, 66-71.
52. DuPont, R. L. & Greene, M. H. (1974). Beginning to dissect a heroin addiction epidemic. In P. Bourne (Ed.), *Addiction* (pp. 101-112). New York: Academic Press.
53. Greene, M. H. & DuPont, R. L. (1974). Heroin addiction trends. *American Journal of Psychiatry*, 131, 545-550.
54. Greene, M. H. & DuPont, R. L. (1974). Heroin use: A communicable disease. *Committee on Problems of Drug Dependence: Report of the 36th Annual Scientific Meeting, National Academy of Sciences, National Academy of Engineering, National Research Council* (pp. 608-629). Mexico City, Mexico.
55. Greene, M. H. & DuPont, R. L. (Eds.) (1974). The epidemiology of drug abuse. *American Journal of Public Health*, 64 (pt 2.), 1-56.
56. Greene, M. H., Luke, J. L. & DuPont, R. L. (1974). Opiate overdose deaths in the District of Columbia: I. Heroin-related fatalities. *Medical Annals of the District of Columbia*, 43, 175-181.
57. Greene, M. H., Luke, J. L. & DuPont, R. L. (1974). Opiate overdose deaths in the District of Columbia: II. Methadone-related fatalities. *Journal of Forensic Sciences*, 19, 575-584.
58. Greene, M. H., Turner, N. & DuPont, R. L. (1974). Amphetamines in the District of Columbia: III. Stimulant abuse in narcotics addicts in treatment with an emphasis on phenmetrazine. *International Journal of the Addictions*, 9, 653-662.
59. Lloyd, R. A., Katon, R. N. & DuPont, R. L. (1974). Evolution of a treatment approach for young heroin addicts: Comparison of three treatment modalities. *International Journal of the Addictions*, 9, 229-239.

60. Brown, B. S., Glendinning, S. T. & DuPont, R. L. (1975). Instances of treatment for opiate and nonopiate drugs in one urban community. *International Journal of the Addictions*, 10, 801-813.
61. Brown, B. S., Greene, M. H. & DuPont, R. L. (1975). Illicit methadone abuse in Washington, DC. In E. Senay, V. Shorty & H. Alksne (Eds.), *Developments in the field of drug abuse* (pp. 444-460). Cambridge, MA: Schenkman Publishing.
62. DuPont, R. L. (1975). Drug abuse in the United States: Possible implications for Nigeria. *Nigerian Medical Journal*, 5, 285-288.
63. DuPont, R. L. (1975). Federal government efforts to provide a solution: An overview. *Proceedings of American Medical Association Symposium on Supplies of Opium for Medical Use* (pp. 62-67). Washington, DC.
64. DuPont, R. L. (1975). Licit opium production and illicit heroin use: What is the relationship? *Proceedings of American Medical Association Symposium on Supplies of Opium for Medical Use* (pp. 30-39). Washington, DC.
65. DuPont, R. L. (1975). Overview of drug abuse. *Proceedings of the First National Drug Abuse Conference* (pp. 25-31). Chicago, IL.
66. DuPont, R. L. (1975). The future of federal drug abuse research: How can we best maximize scarce resources? *Drug and Alcohol Dependence*, 1, 223-240; also published in *Problems of Drug Dependence 197: Proceedings of the 37th Annual Scientific Meeting* (pp. 55-73). Washington, DC: National Academy of Sciences.
67. Greene, M. H., Brown, B. S. & DuPont, R. L. (1975). Controlling the abuse of illicit methadone in Washington, DC. *Archives of General Psychiatry*, 32, 221-226.
68. Greene, M. H. & DuPont, R. L. (1975). The treatment of acute heroin toxicity. In P. Bourne (Ed.), *A treatment manual for acute drug abuse emergencies* (pp. 11-16). (DHEW Publication No. ADM 75-230). Washington, DC: U.S. Government Printing Office.
69. Greene, M. H., Nightingale, S. L. & DuPont, R. L. (1975). Evolving patterns of drug abuse. *Annals of Internal Medicine*, 83, 402-411.
70. Nightingale, S. L., Dormer, R. A. & DuPont, R. L. (1975). Emergency services and drug abuse. *Annals of Internal Medicine*, 83, 569-570.
71. Nightingale, S. L., Dormer, R. A. & DuPont, R. L. (1975). Inappropriate prescribing of psychoactive drugs. *Annals of Internal Medicine*, 83, 896-897.
72. Bass, U. F., Brock, V. W. & DuPont, R. L. (1976). Narcotic use in an inmate population at three points in time. *American Journal of Drug and Alcohol Abuse*, 3, 375-386.

73. DuPont, R. L. (1976). ADAMHA: State of its institutes and relationships to states. *Summary of Proceedings: 3rd Annual Conference of the State and Territorial Alcohol, Drug Abuse and Mental Health Authorities* (pp. 80-85). Denver, Colorado.
74. DuPont, R. L. (1976). Equality for women in drug abuse. In M. Nellis (ed.), *A National Forum Source Book* (pp. 7-13). Washington, DC: National Research and Communications Association.
75. DuPont, R. L. (1976). Marihuana: A conversation with NIDA's Robert L. DuPont. *Science*, 192, 647-649.
76. DuPont, R. L. (1976). NIDA is committed to research. *Proceedings of the 38th Annual Scientific Meeting, College on Problems of Drug Dependence* (pp. 441-444). Richmond, VA: National Academy of Sciences.
77. DuPont, R. L. (1976). Polydrug abuse and the maturing national drug abuse data base. In E. S. Vessell & M. C. Braude (Eds.), *Annals of the New York Academy of Sciences*, 281, 311-320.
78. DuPont, R. L., Dormer, R. A. & Nightingale, S. L. (1976). Treatment of narcotics addiction with narcotic drugs. *Journal of the American Medical Association*, 235(15), 1565-1566.
79. Graham, T. G., Brown, B. S. & DuPont, R. L. (1976). Characteristics of new admissions to a narcotics treatment program: 1970-1974. *International Journal of the Addictions*, 11, 967-976.
80. DuPont, R. L. (1977). Collaboration problems and opportunities. *Proceedings of the International Seminar Commemorating the Designation of the Addiction Research Foundation as a Collaborating Center of the World Health Organization* (pp. 193-202). Toronto, Canada: Alcoholism & Drug Addiction Research Foundation.
81. DuPont, R. L. (1977). Current national heroin trends. *World Journal of Psychosynthesis*, 9, 44-50.
82. DuPont, R. L. (1976). Just what can you tell your patients about marihuana? *Medical Times*, 104, 120-131; also published in 1977 in *Resident & Staff Physician*, 23, 103-110.
83. DuPont, R. L. (1977). Learning from failure and success. *Evaluation*, 4, 150-151.
84. DuPont, R. L. (1977). National strategies for drug abuse prevention: The United States experience. *Proceedings of the 25th Iranian Medical Congress* (pp. 60-73). Ramsar, Iran.
85. DuPont, R. L. (1977). Opening address. In *Proceedings of the CADAP-CEMEF Bi-National Conference on Drug Abuse* (pp. 3-6). El Paso, TX: Southwest Training Institute.
86. DuPont, R. L. (1977). Science, values and the marihuana issue. *Proceedings of the 39th Annual Scientific Meeting, Committee on Problems of Drug Dependence, College on Problems of Drug Dependence* (pp. 41-48). Cambridge, MA.

87. DuPont, R. L. (1977). Treatment as prevention. *Summary of Proceedings: Tripartite Conference on Prevention* (pp. 69-74). Elkridge, MD: U.S. Department of Health, Education, and Welfare.
88. Kozel, N. J. & DuPont, R. L. (1977). *Criminal charges and drug use patterns of arrestees in the District of Columbia*. (DHEW Publication No. ADM 77-427). Washington, DC: U.S. Government Printing Office.
89. Kozel, N. J. & DuPont, R. L. (1977). Trends in drug use and crime and their relationship in an arrestee population. *American Journal of Drug and Alcohol Abuse*, 4, 413-430.
90. Nightingale, S. L. & DuPont, R. L. (1977). Drug abuse and role of physicians. In S. N. Pradham & S. N. Dutta (Eds.), *Drug Abuse: Clinical and Basic Aspects* (pp. 37-45). St. Louis, MO: Mosby.
91. Nurco, D. N. & DuPont, R. L. (1977). A preliminary report on crime and addiction within a community-wide population of narcotic addicts. *Drug and Alcohol Dependence*, 2, 109-121.
92. DuPont, R. L. (1978, September). Bridges between alcohol and drug problems. *Proceedings: ADPA 28th Annual Meeting, Alcohol and Drug Problems Association of North America* (pp. 14-19).
93. DuPont, R. L. (1978). Getting it together for the long haul. *Drug Abuse: Modern Trends, Issues and Perspectives: Proceedings of the 2nd National Drug Abuse Conference* (pp. xiii-xxix). New Orleans, Louisiana.
94. DuPont, R. L. (1978). Marihuana: Our next step. *Drug Abuse and Alcoholism Review*, 1, 14-19; also slightly modified version published in (1977) *Addictions*, 5, 4-9. and (1978) *Focus on Alcohol and Drug Issues*, 1, 7.
95. DuPont, R. L. (1978). New directions for the National Institute on Drug Abuse. In D. E. Smith et al. (Eds.), *A Multicultural View of Drug Abuse: Proceedings of the Fourth National Drug Abuse Conference, San Francisco, California, 1977* (pp. 11-22). Cambridge, MA: Schenkman Publishing.
96. DuPont, R. L. (1978). The drug abuse decade. *Journal of Drug Issues*, 8, 173-187.
97. DuPont, R. L. (1978). The drug abuse legislative agenda 1975. *Drug Abuse: Modern Trends, Issues and Perspectives: Proceedings of the 2nd National Drug Abuse Conference* (pp. 905-911). New Orleans, Louisiana.
98. DuPont, R. L. (1978). You alone can do it, but you cannot do it alone. *Proceedings of the 2nd World Conference of Therapeutic Communities, Part 1* (pp.34-40). Montreal, Canada.
99. Kozel, N. J. & DuPont, R. L. (1978). The heroin use and crime controversy: The issues and some research conclusions. *World Journal of Psychosynthesis*, 10, 42-49.

100. DuPont, R. L. (1980). Marijuana smoking: A national epidemic. *ALA Bulletin*, 66, 2-7.
101. DuPont, R. L. (1980). *Nuclear phobia: Phobic thinking about nuclear power: A discussion with Robert L. DuPont*. Washington, DC: Media Institute; also published in 1981 in A. Hacker, *Nuclear Power in American Thought* (pp.23-41). Washington, DC: Edison Electric Institute.
102. DuPont, R. L. (1980). The future of primary prevention: Parent power. *Journal of Drug Education*, 10, 1-5.
103. DuPont, R. L. & Basen, M. M. (1980). Control of alcohol and drug abuse in industry: A literature review. *Public Health Reports*, 95, 137-148; also published 1982 in R. Parkinson, *Managing Health Promotion in the Workplace: Guidelines for Implementation and Evaluation* (pp. 194-217). Palo Alto, CA: Mayfield Publishing.
104. DuPont, R. L. (1981). Drug abuse: The role of the family. *Phi Delta Epsilon Scientific Journal*, 73, 10-15.
105. DuPont, R. L. (1981, Fall). Fifty million Frenchmen have few nuclear fears. *Electric Perspectives*, 33-36.
106. DuPont, R. L. (1981, May). Sounding the alarm: Marijuana is far from "harmless." *PTA Today*, 3-5.
107. DuPont, R. L. (1981). Why I changed my mind about marijuana. *Listen*, 12-15.
108. DuPont, R. L. (1981, September 7). The nuclear power phobia. *Business Week*, 14-16.
109. Gibbons, C., Brown, B. S., Greene, M. H. & DuPont, R. L. (1981). Initiation into heroin use. *International Journal of the Addictions*, 16, 933-937.
110. DuPont, R. L. (1982). Adverse reactions to marijuana. *Medical Aspects of Human Sexuality*, 16(9), 21.
111. DuPont, R. L. (1982). Drug abuse prevention comes of age in the 1980s. In P. A. Carone, S. F. Yolles, S. N. Kieffer & L. W. Krinsky (Eds.), *Addictive disorders update: Alcoholism, drug abuse, gambling* (pp. 60-106). New York: Human Sciences Press.
112. DuPont, R. L. (1982). Problems of using cocaine as an aphrodisiac. *Medical Aspects of Human Sexuality*, 16(3), 14.
113. DuPont, R. L. (1982). Profile of a phobia treatment program: Two-year follow-up. In R. L. DuPont (Ed.), *Phobia: A Comprehensive Summary of Modern Treatments* (pp. 210-215). New York: Brunner/Mazel.
114. Uhde, T. W., Ballenger, J., Slever, L. J. DuPont, R. L. & Post, R. M. (1982). Animal models of anxiety: Implications for research in humans. *Psychopharmacology Bulletin*, 18, 47-52.

115. DuPont, R. L. (1983, October). Awash in alcohol. *Listen*, 11-14.
116. DuPont, R. L. (1983). Diagnosis and treatment of phobias. *Directions in Psychiatry*, 3(4), 1-7.
117. DuPont, R. L. (1983). Phobias in children. *Journal of Pediatrics*, 102, 999-1002.
118. DuPont, R. L. (1983). Points of view. In D. Upton (Ed.), *Mental Health Care and National Health Insurance* (pp. 205-206). New York: Plenum Press.
119. DuPont, R. L. (1983). Practical pharmacotherapy for phobias. *Directions in Psychiatry*, 3(30), 1-7.
120. DuPont, R. L. (1983). Teenage drug use: Opportunities for the pediatrician. *Journal of Pediatrics*, 102, 1003-1007.
121. DuPont, R. L. (1983). The dangers of "success" against drugs. *Journal of Drug Education*, 13, 201-205.
122. DuPont, R. L. (1984). Bulimia: A modern epidemic among adolescents. *Pediatric Annals*, 13, 908-914.
123. DuPont, R. L. (1984). The treatment and prevention of substance abuse in adolescents. *Directions in Psychiatry*, 4(33), 1-7.
124. DuPont, R. L. (1985). Marijuana, alcohol, and adolescence: A malignant synergism. *Seminars in Adolescent Medicine*, 1, 311-315.
125. DuPont, R. L. (1985). Substance abuse. *Journal of the American Medical Association*, 254, 2335-2337.
126. DuPont, R. L. (1986). Preemployment drug screens. *Journal of the American Medical Association*, 255, 2495-2496.
127. DuPont, R. L. (1986). Substance abuse. *Journal of the American Medical Association*, 256, 2114-2116. Also published in [Japanese edition], *Journal of the American Medical Association*, 255, 110-112.
128. DuPont, R. L. (1987). Cocaine in the workplace: The ticking time bomb. In A. M. Washton & M. S. Gold (Eds.), *Cocaine: A Clinician's Handbook*. New York, NY: Guilford Press.
129. DuPont, R. L. (1987). Discontinuation of benzodiazepine use: A clinician's guide. *Directions in Psychiatry*, 7(12), 1-8.
130. DuPont, R. L. (1987). Phobias. In *Americana Annual* (pp. 67-73). Danbury, CT: Grolier.

131. DuPont, R. L. (1987). Prevention of adolescent chemical dependence. *Pediatric Clinics of North America*, 34, 1-11.
132. Ballenger, J. C., Burrows, G. D., DuPont, R. L., Lesser, I. M., Noyes, R., Pecknold, J. C., et al. (1988). Alprazolam in panic disorder and agoraphobia: Result from a multicenter trial. I. Efficacy in short-term treatment. *Archives of General Psychiatry*, 45, 413-422.
133. DuPont, R. L. (Ed.). (1988). Abuse of benzodiazepines: The problems and the solutions. *American Journal of Drug and Alcohol Abuse*, 14 (Suppl. 1).
134. DuPont, R. L. (1988). The counselor's dilemma: Treating chemical dependence at college. In T. M. Rivinus (Ed.), *Alcoholism/Chemical Dependency and the College Student* (pp. 41-61). New York: The Haworth Press; also appeared in *Journal of College Student Psychotherapy*, 2, 1-61. (1988).
135. DuPont, R. L. (1988). The legacy of Sidney Cohen [Foreword]. In S. Cohen, *The Chemical Brain: The Neurochemistry of Addictive Disorders*. Irvine, CA: CompCare Publishers.
136. DuPont, R. L. (1988). Youth at high risk of chemical dependence: Identification and intervention opportunities for the psychiatrist. *Directions in Psychiatry*, 8(8), 1-8.
137. Eisenach, J., DuPont, R. L., Perkins, J. & Willard, R. (1988). Zero tolerance: Targeting the user. In *Strategy for a Drug-Free America: A Symposium* (pp. 39-45). Washington, DC: Heritage Foundation.
138. Lesser, I. M., Rubin, R. T., Pecknold, J. C., Rifkin, A., Swinson, R. P., Lydiard, R. B., et al. (1988). Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment. *Archives of General Psychiatry*, 45, 437-443.
139. Noyes, R., DuPont, R. L., Pecknold, J. C., Rifkin, A., Rubin, R. T., Swinson, R. P., et al. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. II. Patient acceptance, side effects, and safety. *Archives of General Psychiatry*, 45, 423-248.
140. DuPont, R. L. (1989, March 27). A doctor's case for random drug tests. *The Washington Times*.
141. DuPont, R. L. (1989, October). Addiction, withdrawal, and the role of BZs. *Psychiatric Times*.
142. DuPont, R. L. (1989, January 22). Avoiding nostrums and illusions in the war on drugs. *Los Angeles Times*, pp. 3-5.
143. DuPont, R. L. (1989). Drug abuse: A global perspective focusing on the third world. In *Issues '88* (pp. 97-107). New York: Global Economic Action Institute.
144. DuPont, R. L. (1989, January). Drug legalization: Should we just say yes? *Listen*, 11-13.

145. DuPont, R. L. (1989). Drugs in the American workplace: Conflict and opportunity. Part I: Epidemiology of drugs at work. *Social Pharmacology*, 3, 133-146.
146. DuPont, R. L. (1989). Drugs in the American workplace: Conflict and opportunity. Part II: Controversies in workplace drug use prevention. *Social Pharmacology*, 3, 147-164.
147. DuPont, R. L. (1989, Spring). Never trust anyone under 40: What employers should know about drugs in the workplace. *Policy Review*, 52-57.
148. DuPont, R. L. (1989, September). Prevention now: For life and leisure. In *Report of the seventh world congress for the prevention of alcoholism and drug dependency* (pp. 33-35). Nampa, ID: Pacific Press.
149. DuPont, R. L. (1989, April 16). The case for mandatory, universal drug tests. *The Washington Post*, p. B8.
150. DuPont, R. L. (1989). Why not legalise drugs? *Good Health*, 21(3), 22-25.
151. Lesser, I. M., Rubin, R. T., Rifkin, A., Swinson, R. P., Ballenger, J. C., Burrows, G. D., et al. (1989). Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. *Journal of Affective Disorders*, 16, 49-58.
152. DuPont, R. L. (1990). A physician's guide to discontinuing benzodiazepine therapy. *Western Journal of Medicine*, 152(5), 600-603.
153. DuPont, R. L. (1990). A practical approach to benzodiazepine discontinuation. *Journal of Psychiatric Research*, 24, 81-90.
154. DuPont, R. L. (1990). Addictive potential of benzodiazepines "overrated." *Clinical Psychiatry News*, 18(7).
155. DuPont, R. L. (1990). Benzodiazepines and chemical dependence: Guidelines for clinicians. *Substance Abuse*, 11, 232-236.
156. DuPont, R. L. (1990). Introduction. In *Youth and Drugs: Society's Mixed Messages* (OSAP Prevention Monograph-6). Rockville, MD: Office for Substance Abuse Prevention.
157. DuPont, R. L. (1990, October). Benzodiazepines and chemical dependence: Clinical guidelines. In *Practical Clinical Management: Drug Abuse Education for the primary Care Physician* (Monograph of Conference Proceedings, pp. 51-59). Baltimore Medical and Chirurgical Faculty of Maryland.
158. DuPont, R. L. (1990). Mandatory random testing needs to be undertaken at the worksite. In R. C. Engs (Ed.), *Controversies in the Addiction Field: Volume One* (pp. 105-111). Dubuque, IA: Kendall/Hunt.

159. DuPont, R. L. (1990). Medicines and drug testing in the workplace. *Journal of Psychoactive Drugs*, 22, 451-459.
160. DuPont, R. L. (1990). Policy concerns: Addiction, anxiety and benzodiazepines: A public policy perspective. In B. B. Wilford (Ed.), *Balancing the Response to Prescription Drug Abuse: Report of a National Symposium on Medicine and Public Policy* (pp. 109-117). Chicago: American Medical Association, Department of Substance Abuse.
161. DuPont, R. L. (1990). Saying 'no' to heroin use: A dilemma in a free society [Foreword]. In W. H. McGlothlin & M. D. Anglin (Eds.), *The Compulsory Treatment of Opiate Dependence*. New York: Haworth Press.
162. DuPont, R. L. (1990). The "morphine positive" problem. *Zero Tolerance*, 1(1), 2.
163. DuPont, R. L. (1990). Thinking about stopping treatment for panic disorder. *Journal of Clinical Psychiatry*, 51(suppl. A), 38-45.
164. DuPont, R. L. & Goldfarb, R. L. (1990, January 26). Drug legalization: Asking for trouble. *The Washington Post*, p. A22.
165. DuPont, R. L., Saylor, K. E. & Latimer, S. (1990, August). Drug testing: Know your options. *Corrections Today*, 168-170.
166. Rifkin, A. Pecknold, J. C., Swinson, R. P., Ballenger, J. C., Burrows, G. D., Noyes, R., et al. (1990). Sequence of improvement in agoraphobia with panic attacks. *Journal of Psychiatric Research*, 24, 1-8.
167. Saylor, K. E., DuPont, R. L. & Brouillard, M. (1990). Self-help treatment of anxiety disorders. In R. Noyes, M. Roth & G. D. Burrows (Eds.), *Handbook of Anxiety: Volume 4: The Treatment of Anxiety*(pp. 483-496). Amsterdam: Elsevier.
168. DuPont, R. L. (1991). Effective Employee Assistance Programs. In J. A. Eisenach & A. J. Cowin (Eds.), *How to Ensure a Drug-Free Congressional Office: A Heritage Foundation Seminar for Members of Congress and Congressional Staff* (pp. 29-36). Washington, DC: The Heritage Foundation.
169. DuPont, R. L. (1991, July). Interrelationships and differences exist among three diagnostic groups. *Psychiatric Times*, 37-38.
170. DuPont, R. L. (1991). NIDA's role in applied research. In S. W. Gust, J. M. Walsh, L. B. Thomas & D. J. Crouch (Eds.), *Drugs in the Workplace: Research and Evaluation Data, Volume II* (DHHS Publication No. ADM 91-1730, pp. 225-230). Washington, DC: U.S. Government Printing Office.

171. DuPont, R. L. (1991). Should welfare mothers be tested for drugs? In J. A. Eisenach (Ed.), *Winning the Drug War: New Challenges for the 1990s* (pp. 83-95). Washington, DC: Heritage Foundation.
172. DuPont, R. L. & McGovern, J. P. (1991). Co-dependence: A new diagnosis, Part I. *Directions in Psychiatry, 11*(9), 1-8.
173. DuPont, R. L. & McGovern, J. P. (1991). Co-dependence: A new diagnosis, Part II. *Directions in Psychiatry, 11*(10), 1-8.
174. DuPont, R. L. & McGovern, J. P. (1991). The growing impact of the Children-of-Alcoholics movement on medicine: A revolution in our midst. In T. M. Rivinus (Ed.), *Children of Chemically Dependent Parents: Multiperspectives from the Cutting Edge* (pp. 313-329). New York: Brunner/Mazel.
175. DuPont, R. L. & Saylor, K. E. (1991). Sedatives/hypnotics and benzodiazepines. In R. J. Frances & S. I. Millet (Eds.), *Clinical Textbook of Addictive Disorders* (pp. 69-102). New York, NY: Guilford Press.
176. McGovern, J. P. & DuPont, R. L. (1991). Student Assistance Programs: An important approach to drug abuse prevention. *Journal of School Health, 61*, 260-264.
177. Voth, E. A., DuPont, R. L. & Voth, H. M. (1991). Responsible prescribing of controlled substances. *American Family Physician, 44*, 1673-1678.
178. DuPont, R. L. (1992). Advances in the treatment of anxiety disorders, Part I: Psychological treatments. *Directions in Psychiatry, 12*(24), 1-8.
179. DuPont, R. L. (1992). Advances in the treatment of anxiety disorders, Part II: Pharmacological treatments. *Directions in Psychiatry, 12*(25), 1-8.
180. DuPont, R. L. (1992). Choosing the right treatment for the patient with anxiety. *Modern Medicine, 60*, 64-76.
181. DuPont, R. L. & McGovern, J. P. (1992). Suffering in addiction: Alcoholism and drug dependence. In P. L. Starck & J. P. McGovern (Eds.), *The Hidden Dimension of Illness: Human Suffering* (pp. 155-201). New York: National League for Nursing.
182. DuPont, R. L. & Saylor, K. E. (1992). Advances in the treatment of anxiety disorders: A therapist's guide. *Directions in Rehabilitation Counseling, 3*(4), 1-27.
183. DuPont, R. L. & Saylor, K. E. (1992). Depressant substances in adolescent medicine. *Pediatrics in Review, 13*, 381-386.

184. DuPont, R. L., Swinson, R. P., Ballenger, J. C., Burrows, G. D., Noyes, R., Rubin, R. T., et al. (1992). Discontinuation effects of alprazolam after long-term treatment of panic-related disorders. *Journal of Clinical Psychopharmacology*, *12*, 352-354.
185. DuPont, R. L. & Wish, E. D. (1992). Operation Tripwire revisited. *The Annals of the American Academy of Political and Social Science*, *521*, 91-111.
186. Lesser, I. M., Lydiard, R. B., Antal, E., Rubin, R. T., Ballenger, J. C. & DuPont, R. L. (1992). Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. *American Journal of Psychiatry*, *149*, 1556-1562.
187. Lydiard, R. B., Lesser, I. M., Ballenger, J. C., Rubin, R. T., Laraia, M. & DuPont, R. L. (1992). A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. *Journal of Clinical Psychopharmacology*, *12*, 96-103.
188. McGovern, J. P. & DuPont, R. L. (1992). Co-dependence: The other half of addiction. *Houston Medicine*, *8*, 5-11.
189. DuPont, R. L. (1993). Anxiety and the BZs. *ADAA Reporter*, *IV*(3), 1, 5-6.
190. DuPont, R. L. (1993). Benzodiazepines, addiction, and public policy. *New Jersey Medicine*, *90*, 823-826.
191. DuPont, R. L. (1993). Foreword. In G. R. Ross, *Treating Adolescent Substance Abuse: Understanding the Fundamental Elements* (pp. xi-xii). Boston: Allyn & Bacon.
192. DuPont, R. L. (1993, June). Research into drug abuse. *Drugs & Violence in America: Proceedings on the Inaugural Symposium on Crime and Punishment in the United States* (pp. 69-75). Washington, DC: U.S. Sentencing Commission.
193. Glantz, L. H. & DuPont, R. L. (1993). Issue 3: Does drug testing violate civil rights? Yes/No. In R. Goldberg (Ed.), *Taking Sides: Clashing Views on Controversial Issues in Drugs and Society* (pp. 50-69). Guilford, CT: Dushkin Publishing.
194. Sellers, E. M., Ciraulo, D. A., DuPont, R. L., Griffiths, R. R., Kosten, T. R., Romach, M. K., et al. (1993). Alprazolam and benzodiazepine dependence. *Journal of Clinical Psychiatry*, *54*(Suppl.), 64-74.
195. DuPont, R. L. (1994). Facing and preventing teenage use of alcohol and other drugs. *Directions in Substance Abuse Counseling*, *2*(3), 1-12.
196. DuPont, R. L. (1994). Laboratory diagnosis [Chapter 2]. In N. S. Miller (Ed.), *Principals of Addiction Medicine* (pp. 1-8). Chevy Chase, MD: American Society of Addiction Medicine.
197. DuPont, R. L. (1994, March). Ten winning ways to drug-proof your kids: A parent's quick guide. *Parents' Association to Neutralize Drug and Alcohol Abuse Newsletter*, *XV*(1), 1-2.

198. DuPont, R. L. (1994). The twelve step approach. In N.S. Miller (Ed.), *Treating Coexisting Psychiatric and Addictive Disorders: A Practical Guide* (pp. 177-197). Center City, MN: Hazelden.
199. DuPont, R. L. & DuPont, C. M. (1994). The treatment of anxiety: Realistic expectations and risks posed by controlled substances. *Journal of Law, Medicine & Ethics*, 22, 5-13.
200. DuPont, R. L. & MacKenzie, D. L. (1994). Narcotics and drug abuse: An unforeseen tidal wave. In J. A. Conley (Ed.), *The 1967 President's Crime Commission Report: Its Impact 25 Years Later* (pp. 121-144). Cincinnati, OH: Anderson Publishing.
201. DuPont, R. L. & Shiraki, S. (1994). Recent research in 12-step programs [Chapter 5]. In N. S. Miller (Ed.), *Principals of Addiction Medicine* (pp. 1-10). Chevy Chase, MD: American Society of Addiction Medicine.
202. DuPont, R. L. & Verebey, K. (1994). The role of the laboratory in the diagnosis of LSD and Ecstasy psychosis. *Psychiatric Annals*, 24, 142-144.
203. DuPont, R. L. (1995). Anxiety and addiction: A clinical perspective on comorbidity. *Bulletin of the Menninger Clinic*, 59(Suppl. A), A53-A72.
204. DuPont, R. L. (1995). Overcoming teenage addiction: Working with families and the role of 12-step programs [Special Report]. *Directions in Substance Abuse Counseling*, 3, 1-12.
205. DuPont, R. L. (1995). Treating obsessive-compulsive disorder. *Directions in Psychiatry*, 15(4), 1-8.
206. DuPont, R. L. & Baumgartner, W. A. (1995). Drug testing by urine and hair analysis: Complementary features and scientific issues. *Forensic Science International*, 70, 63-76.
207. DuPont, R. L. & Gold, M. S. (1995). Naltrexone (ReVia): A new option for the treatment of alcohol dependence. *Directions in Psychiatry*, 15(26), 1-8.
208. DuPont, R. L. & Gold, M.S. (1995). Withdrawal and reward: Implications for detoxification and relapse prevention. *Psychiatric Annals*, 25, 663-668.
209. a. DuPont, R. L., Griffin, D. W., Siskin, B. R., Shiraki, S. & Katze, E. (1995). Random drug tests at work: The probability of identifying frequent and infrequent users of illicit drugs. *Journal of Addictive Diseases*, 14, 1-17.
- b. DuPont, R. L., Griffin, D. W., Siskin, B. R., Shiraki, S. & Katze, E. (1995). Random drug tests at work: Does it primarily identify casual or regular drug users? *Employment Testing*, 4(1), 6-13.
210. DuPont, R. L. Rice, D. P., Shiraki, S. & Rowland, C. R. (1995). Economic costs of obsessive-compulsive disorder. *Medical Interface*, 8, 102-109.

211. DuPont, R. L. & Voth, E. A. (1995). Drug legalization, harm reduction, and drug policy. *Annals of Internal Medicine*, 123, 461-465.
212. Goldstein, D. J., Wilson, M. G., Thompson, V. L., Potvin, J. H., Rampey, A. H. & the Fluoxetine Bulimia Nervosa Research Group (DuPont RL et al). Long-term fluoxetine treatment of bulimia nervosa. *British Journal of Psychiatry*, 166, 660-666.
213. DuPont, R. L. (1996, July/August). Do random workplace drug tests primarily identify casual or regular drug users? *MRO Update*, 5-7.
214. DuPont, R. L. (1996). Harm reduction and decriminalization in the United States: A personal perspective. *Substance Use & Misuse*, 31, 1929-1945.
215. DuPont, R. L. (1996). Overcoming adolescent addiction: Working with families and the role of 12-step programs. In *The Hatherleigh Guide to Treating Substance Abuse, Part II* (pp. 139-158). New York: Hatherleigh Press.
216. DuPont, R. L. (1996). Therapeutic approaches to anxiety disorders. In *The Hatherleigh Guide to Psychiatric Disorders* (pp. 97-118). New York: Hatherleigh Press.
217. DuPont, R. L., DuPont, C. M. & Spencer, E. D. (1996). Anxiety disorders in the elderly. *Directions in Psychiatry*, 16(14), 1-12.
218. DuPont, R. L. & Gold, M. S. (1996). Naltrexone pharmacotherapy for the treatment of alcohol dependence. In *The Hatherleigh Guide to Treating Substance Abuse, Part I* (pp. 63-83). New York: Hatherleigh Press.
219. DuPont, R. L. & Gold, M. S. (1996). Naltrexone pharmacotherapy for the treatment of alcohol dependence: An update. *Essential Psychopharmacology*, 1, 136-151.
220. DuPont, R. L. & McGovern, J. P. (1996). Co-dependence. In *The Hatherleigh Guide to Issues in Modern Therapy* (pp. 69-92). New York: Hatherleigh Press.
221. DuPont, R. L. & McGovern, J. P. (1996). Introduction. In *The Hatherleigh Guide to Issues in Modern Therapy*(pp. xi-xiv). New York: Hatherleigh Press.
222. DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R. & Harwood, H. J. (1996). Economic costs of anxiety disorders. *Anxiety*, 2, 167-172.
223. Schatzberg, A. F., Cohen, L. & DuPont, R. L. (1996, September). SSRI treatment controversies: The anxious depressed patient. Intercom: The experts converse. *Journal of Clinical Psychiatry*, 1-11.
224. Schatzberg, A. F., Siegal, A. & DuPont, R. L. (1996, July). SSRI treatment controversies: The elderly. Intercom: The experts converse. *Journal of Clinical Psychiatry*, 1-11.

225. DuPont, R. L. (1997). Drug testing. In N. S. Miller, M. S. Gold & D. E. Smith (Eds.), *Manual of Therapeutics for Addictions* (pp. 86-94). New York: Wiley-Liss.
226. DuPont, R. L. (1997). Panic disorder and addiction: The clinical issues of comorbidity. *Bulletin of the Menninger Clinic*, 61(Suppl. A), A54-A65.
227. DuPont, R. L. (1997). Psychotherapy in addictive disorders. In N. S. Miller (Ed.), *Addictions in Psychiatry* (pp. 370-377). Philadelphia, PA: W. B. Saunders Co.
228. DuPont, R. L. (1997). The pharmacology and drug interactions of the newer antidepressants. *Essential Psychopharmacology*, 2, 7-32.
229. DuPont, R. L. (1997). Violence and drugs. *Journal of Psychoactive Drugs*, 29, 303-305.
230. DuPont, R. L. (1997, April). Welfare and drug tests. *MRO Update*, 1-3.
231. DuPont, R. L., Valk, T. H. & Heltberg, J. (1997). Psychiatric illness and stress. In H. L. DuPont & R. Steffen (Eds.), *Travel Medicine* (pp. 253-257). Hamilton, Ontario: B. C. Decker, Inc.
232. Wilson, J. O., Ross, J. & DuPont, R. L. (1997, March/April). Anxiety disorders in managed care. *Behavioral Health Management*, 33-38.
233. DuPont, R. L. (1998). Addiction: A new paradigm. *Bulletin of the Menninger Clinic*, 62, 231-242.
234. DuPont, R. L. (1998). Curbing addictive behaviors. In J. Mandell, *What to Expect in Your Fifties: A Woman's Guide to Health, Vitality, and Longevity* (pp. 294-300). New York: Bantam Doubleday Dell.
235. DuPont, R. L. (1998). Implications for prevention policy: A commentary. In W. J. Bukoski & R. I. Evans (Eds.), *Cost-benefit/cost effectiveness research of drug abuse prevention: Implications for programming and policy* (DHHS Publication No. NIH 98-4021, pp. 214-221). Washington, DC: U.S. Government Printing Office.
236. DuPont, R. L. & DuPont, C. M. (1998). Sedatives/hypnotics and benzodiazepines. In R. J. Frances & S. I. Miller (Eds.), *Clinical Textbook of Addictive Disorders* (2nd ed., pp. 120-149). New York, NY: Guilford Publications.
237. Macdonald, D. I. & DuPont, R. L. (1998). The role of the medical review officer. In A. G. Graham, T. S. Schultz & B. B. Wilford (Eds.), *Principles of Addiction Medicine* (2nd ed., pp. 1255-1262). Chevy Chase, MD: American Society of Addiction Medicine.
238. Anderson, D. J., McGovern, J. P. & DuPont, R. L. (1999). The origins of the Minnesota model of addiction treatment: A first-person account. *Journal of Addictive Diseases*, 18(1), 107-110.

239. Chappel, J. N. & DuPont, R. L. (1999). Twelve-step and mutual-help programs for addictive disorders. *Psychiatric Clinics of North America*, 22(2), 425-446.
240. Davison, J. R., DuPont, R. L., Hedges, D. & Haskins, J. T. (1999). Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. *Journal of Clinical Psychiatry*, 60, 528-535.
241. DuPont, R. L. (1999). Biology and the environment: Rethinking demand reduction. *Journal of Addictive Diseases*, 18(4), 121-138.
242. DuPont, R. L. (1999). Diagnostic testing: Laboratory and psychological. In M. Galanter & H. D. Kleber (Eds.), *American Psychiatric Press Textbook of Substance Abuse Treatment* (2nd ed., pp. 521-527). Washington, DC: American Psychiatric Press.
243. DuPont, R. L. (1999, April 27). Medicine, not pot. *The Washington Post*, p. A17.
244. DuPont, R. L. (1999). Examining the debate on the use of medical marijuana. *Proceedings of the Association of American Physicians*, 111(2), 166-172.
245. DuPont, R. L., DuPont, C. M. & Spencer, E. D. (1999). Generalized anxiety disorder: A clinician's guide to "the worry disease." *Directions in Psychiatry*, 14(2), 133-143.
246. Kessler, R. C., Stein, M., DuPont, R. L., Berglund, P. & Wittchen, H. (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. *American Journal of Psychiatry*, 156, 1915-1923.
247. Jacobs, W., DuPont, R. L. & Gold, M. S. (1999). Drug testing and the DSM-IV. *Psychiatric Annals*, 30(9), 583-588.
248. DuPont, R. L. (2000, Summer). Anxiety over two centuries. *ADAA Reporter*, 17-19.
249. DuPont, R. L. (2001). Drugs, crime and race. *Psychiatric Times*, 18(2), 1, 8, 10-11.
250. DuPont, R. L. (2001). Laboratory and psychological testing in addiction medicine. In G. O. Gabbard (Ed.), *Treatment of Psychiatric Disorders* (3rd ed., pp. 655-662). Washington, DC: American Psychiatric Press.
251. DuPont, R. L. & DuPont, C. M. (2001). Social phobia: A discrete disorder? *Directions in Psychiatry*, 21(10), 139-158.
252. DuPont, R. L. (2002). Clinical approaches for drug offenders. In C. G. Leukefeld, F. Tims & D. Farabee (Eds.), *Treatment of Drug Offenders: Policies and Issues* (pp. 57-68). New York: Springer Publishing.
253. DuPont, R. L. (2002). EP interview with Dr. DuPont. *Essential Psychopharmacology*, 5(3), 237-250.

254. DuPont, R. L. (2002). Heroin addiction in the nation's capital (1966-1973). In D. F. Musto (Ed.), *One Hundred Years of Heroin*(pp. 67-90). New Haven, Connecticut: Yale University.
255. DuPont, R. L. (2002). Self-medication and anxiety disorders. *ADAA Reporter*, 13(1), 9-11.
256. DuPont, R. L. (2002). Social anxiety during the holidays. *ADAA Reporter*, 13(6), 1, 8-9.
257. DuPont, R. L., DuPont, C. M. & Rice, D. P. (2002). Economic costs of anxiety disorders. In D. J. Stein & E. Hollander (Eds.), *Textbook of Anxiety Disorders* (pp. 475-483). Washington, DC: American Psychiatric Press.
258. DuPont, R. L., Spencer, E. D. & DuPont, C. M. (2002, December 3). Terrorism: Anxiety on a global scale [Online article]. *American Council on Science and Health: HealthFactsandFears.com*
259. DuPont, R. L., Valk, T. H. & Heltberg, J. (2002). Psychiatric illness and stress. In H. L. DuPont & R. Steffan (Eds.), *Textbook of Travel Medicine and Health* (2nd ed., pp. 253-257). Hamilton, Ontario: B. C. Decker, Inc.
260. Sheehan, D. V., DuPont, R. L., Kalali, A. H., Yang, H., Barbato, L. M., Harnett-Sheehan, K. et al. (2002). Assessing improvement of disability using Sheehan Disability Scale in subjects with generalized social anxiety disorder [Abstracts from the XXIII CINP Congress, Montréal, June 23-27, 2002]. *International Journal of Neuropsychopharmacology*, 5(5, Suppl. 1), P.4.W.058.
261. DuPont, R. L. & DuPont, C. M. (2003). Sedatives/hypnotics and benzodiazepines. In D. H. Barlow (Ed.), *Clinical Textbook of Addictive Disorders* (3rd ed., pp. 219-240). New York, NY: Guilford Press.
262. DuPont, R. L. & Saylor, K. E. (2003). Drug tests in prevention research. In Z. Sloboda & W. Bukoski (Eds.), *Handbook of Drug Abuse Prevention: Theory, Science, and Practice* (pp. 199-215). New York: Kluwer Academic/Plenum.
263. DuPont, R. L. & Selavka, C. M. (2003). Drug testing addiction treatment and criminal justice settings. In A. W. Graham, T. K. Schultz, M. F. Mayo-Smith, R. K. Ries & B. B. Wilford (Eds.), *Principals of Addiction Medicine* (3rd ed., pp. 1001-1008). Chevy Chase, MD: American Society of Addiction Medicine.
264. DuPont, R. L. (2003). Foreword. In L. Scott, *The Sober Kitchen: Recipes and Advice for a Lifetime of Sobriety*. Boston: Harvard Common Press.
265. DuPont, R. L. & Selavka, C. M. (2003). Laboratory and psychological diagnostic testing. In M. Galanter & H. D. Kleber (Eds.), *American Psychiatric Press Textbook of Substance Abuse Treatment* (3rd ed., pp. 587-595). Washington, DC: American Psychiatric Press.

266. Macdonald, D. I. & DuPont, R. L. (2003). The role of the medical review officer. In A. W. Graham, T. K. Schultz, M. F. Mayo-Smith, R. K. Ries & B. B. Wilford (Eds.), *Principles of Addiction Medicine* (3rd ed., pp. 977-986). Chevy Chase, MD: American Society of Addiction Medicine.
267. Tullis, L. M., DuPont, R. L., Frost-Pineda, K. & Gold, M. S. (2003). Marijuana and tobacco: A major connection? *Journal of Addictive Diseases*, 22(3), 51-62.
268. DuPont, R. L. (2003, January). Prevention, not punishment. *American School Board Journal*, 190(1), 25-26.
269. DuPont, R. L. (2005). At issue: Should marijuana laws be relaxed? *CQ Researcher*, 15(6), 141.
270. DuPont, R. L. (2005). Editor's notes. *Essential Psychopharmacology*, 6(5), iv-v.
271. a. DuPont, R. L. (Ed.). (2005). Prescription stimulant abuse. *Psychiatric Annals*, 35(3).
- b. DuPont, R. L. (2005). Prescription stimulant abuse [Editorial]. *Psychiatric Annals*, 35(3), 193-197.
- c. DuPont, R. L. & Bensinger, P. B. (2005). Abuse-resistant drug delivery. *Psychiatric Annals* 35(3), 253-256.
272. DuPont, R. L. & Kaplan, E. M. (2005). Benzodiazepines and anxiety disorders: A review for the practicing physician. *Current Medical Research and Opinions*, 21(6), 941-950.
273. Coleman, J. J., Bensinger, P. B., Gold, M. S., Smith, D. E., Bianchi, R. P. & DuPont, R. L. (2005). Can drug design inhibit abuse? *Journal of Psychoactive Drugs*, 37(4), 343-362.
274. DuPont, R. L. (2006, March). Drugged driving: A new opportunity. *Drug Watch World News*, 11(1), 13.
275. a. DuPont, R. L. (Ed.). (2006). Prescription stimulant abuse. *Pediatric Annals*, 35(8).
- b. DuPont, R. L. (2006). Prescription stimulant abuse [Editorial]. *Pediatric Annals*, 35(8), 534-537.
- c. DuPont, R. L. & Bensinger, P. B. (2006). Abuse-resistant drug delivery. *Pediatric Annals* 35(8), 587-592.
276. White, W. L., DuPont, R. L. & Skipper, G. E. (2007). Physician health programs: What counselors can learn from these remarkable programs. *Counselor*, 8(2), 42-47.
277. DuPont, R. L. (2007). Improving highway safety: It's not just about alcohol. *Second National Leadership Conference on Medical Education in Substance Abuse*. White House Office of

National Drug Control Policy, 9-11.

278. DuPont, R. L. (2007). Foreword. In A. M. Ghadirian, *Alcohol and Drug Abuse: A Psychosocial and Spiritual Approach to Prevention*.
279. DuPont, R. L., Bucher, R. H., Wilford, B. B., Coleman, J. J. (2007). School-based administration of ADHD drugs decline, along with diversion, theft, and misuse. *The Journal of School Nursing* 23(6), 349-352.
280. Wilford, B. B. & DuPont, R. L. (2007). Diversion, abuse, and other nonmedical use of prescription drugs. In T. R. Fulda & A. I Wertheimer (Eds.), *Handbook of Pharmaceutical Public Policy* (1st ed., pp. 499-529). Binghamton, NY: Pharmaceutical Products Press: Haworth Press.
281. DuPont, R. L., Greene, W. M. & Lydiard, R. B. (2007). Sedatives and hypnotics: Clinical use and abuse. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
282. DuPont, R. L., Greene, W. M. & Lydiard, R. B. (2007). Sedatives and hypnotics: Pharmacology and epidemiology. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
283. a. DuPont, R. L. & Gold, M. S. (2007). Comorbidity and “self-medication.” *Journal of Addictive Diseases*, 26(1), 13-23.
- b. DuPont, R. L. & Gold, M. S. (2007). Comorbidity and “self-medication.” In M. S. Gold (Ed.), *Dual Disorders: Nosology, Diagnosis, and Treatment Confusion – Chicken or Egg?* Binghamton, NY: The Haworth Medical Press.
284. The Betty Ford Institute Consensus Panel. (2007). What is recovery? A working definition from the Betty Ford Institute. *Journal of Substance Abuse Treatment*, 33, 221-228.
285. a. DuPont, R. L., Skipper, G. E. & White, W. L. (2007). Testing for recent alcohol use. *Employee Assistance Digest*, 28(1), 15-21.
- b. DuPont, R. L., Skipper, G. E. & White, W. L. (2008). Testing for recent alcohol use. *Counselor*, 9(2), 44-51.
- c. DuPont, R. L., Skipper, G. E. & White, W. L. (2008). Testing for recent alcohol use. *Student Assistance Journal*, 20(1), 12-18.
- d. Skipper, G. E., DuPont, R. L. & White, W. L. (2008). Testing for recent alcohol use. *Perspectives: The Journal of the American Probation and Parole Association*, 32(3), 38-45.
286. DuPont, R. L. & Selavka, C. S. (2008). Testing to identify recent drug use. In M. Galanter & H. D. Kleber (Eds.), *American Psychiatric Press Textbook of Substance Abuse Treatment* (4th ed., pp. 655-664). Washington, DC: American Psychiatric Press.

287. DuPont, R. L., Coleman, J. J., Bucher, R. H., Wilford, B. B. (2008). Characteristics and motives of college students who engage in nonmedical use of methylphenidate. *The American Journal on Addictions*, 17(3), 167-171.
288. Parran, T. V., Wilford, B. B. & DuPont, R. L. (2008). Prescription drug abuse. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
289. Skipper, G. E. & DuPont, R. L. (2008). Substance abuse among physicians and other health professionals. In *Encyclopedia of Drugs, Alcohol & Addictive Behaviors* (3rd ed., pp. 242-251).
290. DuPont, R. L. (2008). Addiction in Medicine. In *Transactions of the American Clinical and Climatological Association*, 119, 227-241.
291. McLellan, A. T., Skipper, G. E., Campbell, M. G. & DuPont, R. L. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. *British Medical Journal*, 337:a2038.
292. DuPont, R. L. (2008). Foreword. In J. Hartelius, *Narcotic Drug Control in Sweden: The Post War Experience*. Stockholm: Fri Publishing Company.
293. DuPont R. L., McLellan A. T., White W. L., Merlo L., and Gold M. S. (2009). Setting the standard for recovery: Physicians Health Programs evaluation review. *Journal for Substance Abuse Treatment*, 36(2), 159-171.
294. Gold, M. S. & DuPont, R. L. (2009). Making Sense of the Future [Editorial]. *Clinical Psychiatry News*, 37(2), 4.
295. DuPont, R. L. (2009). Reflections on the early history of National Institute on Drug Abuse (NIDA): Implications for today. *Journal of Drug Issues*, 39(1), 5-14.
296. DuPont, R. L., McLellan, A. T., Carr, G., Gendel, M & Skipper, G. E. (2009). How are addicted physicians treated? A national survey of physician health programs. *Journal of Substance Abuse Treatment*, 37, 1-7.
297. Skipper, G. E., Campbell, M. D. & DuPont, R. L. (2009). Anesthesiologists with substance use disorders: A 5-year outcome study from 16 state Physician Health Programs. *Anesthesia & Analgesia*, 109(3), 891-896.
298. DuPont, R. L., Goldberger, B. A. & Gold, M. S. (2009). Clinical and legal considerations in drug testing. In R. K. Ries, D. Fiellin, S. C. Miller & R. Saitz (Eds.) *Principals of Addiction Medicine* (4th ed., pp. 1499-1507). Philadelphia, PA: Lippincott Williams & Wilkins.
299. DuPont, R. L. (2009). Workplace drug testing and the role of the medical review officer. In R. K. Ries, D. Fiellin, S. C. Miller & R. Saitz (Eds.) *Principals of Addiction Medicine* (4th ed., pp. 1508-1511). Philadelphia, PA: Lippincott Williams & Wilkins.

300. DuPont, R. L. (2009). An appraisal of present and future U.S. drug policy. In P. J. Robson (Ed.) *Forbidden Drugs* (3rd ed., pp. 230-234). New York, NY: Oxford University Press.
301. DuPont, R. L., Bailey, J. A. & Teitelbaum, S. A. (2009). Cannabis (marijuana) use disorders in adults: Clinical features and diagnosis. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
302. Teitelbaum, S. A., DuPont, R. L. & Bailey, J. A. (2009). Cannabis (marijuana) use disorders in adults: Treatment, prognosis, and long-term medical effects. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
303. Bailey, J. A., DuPont, R. L. & Teitelbaum, S. A. (2009). Cannabis (marijuana) use disorders in adults: Epidemiology, comorbidity, and pathogenesis. In B. D. Rose (Ed.), *UpToDate*. Waltham, MA: UpToDate.
304. DuPont, R. L. (2009). Drug testing in clinical settings. *The Journal of Global Drug Policy and Practice* 3(4).
305. McKay, J., Carise, D., Dennis, M. L., DuPont, R. L., Humphreys, K., et al. (2009). Second Betty Ford Institute Conference Extending the Benefits of Addiction Treatment: Practical Strategies for Continuing Care and Recovery. *Journal of Substance Abuse Treatment*, 36(2), 127-130.
306. DuPont, R. L. (2010). Present at the creation: NIDA's first five years. *Drug and Alcohol Dependence*, 107(1), 82-87.
307. Caulkins, J. P. & DuPont, R. L. (2010). Is 24/7 Sobriety a good goal for repeat driving under the influence (DUI) offenders? [Editorial]. *Addiction*, 105, 575-577.
308. DuPont, R. L., Shea, C. L., Talpins, S. K. & Voas, R. (2010). Leveraging the criminal justice system to reduce alcohol- and drug-related crime. *The Prosecutor*, 44(1), 38-42.
309. DuPont, R. L. & White, W. L. (2010). Practicing physicians can combat addiction and promote lifelong recovery. *The Bulletin*, 73(3).
310. Larsson, M. & DuPont, R. L. (2010, May 24). Children: global victims of drug abuse. Stockholm, Sweden: World Federation Against Drugs.
311. Coleman, J. J., Schuster, C. R. & DuPont, R. L. (2010). Reducing the abuse potential of controlled substances. *Pharmaceutical Medicine*, 24(1), 21-36.
312. DuPont, R. L. (2010). Prescription drug abuse: An epidemic dilemma. *Journal of Psychoactive Drugs*, 42(2), 127-132.
313. DuPont, R.L., Logan, B.K. & Talpins, S.K. (2010, Summer). New strategies to curb drugged driving. *Between the Lines*, 18(4), 1-2.

314. Arria, A. M. & DuPont, R. L. (2010). Nonmedical prescription stimulant use among college students: Why we need to do something and what we need to do. *Journal of Addictive Diseases*, 29(4), 417-426.
315. Skipper, G. E. & DuPont, R. L. (2010). U.S. Physician Health Programs: A model of successful treatment of addictions. *Counselor*, 11(6), 22-29.
316. Skipper, G. E. & DuPont, R. L. (2011). The Physician Health Program: A replicable model of sustained recovery management. In J. F. Kelly & W. L. White (Eds.), *Addiction Recovery Management: Theory, Research and Practice* (pp. 281-299). New York: Science+Business Media, LLC.
317. DuPont, R. L. & Humphreys, K. (2011). A new paradigm for long-term recovery. *Substance Abuse*, 32(1), 1-6.
318. Talpins, S. K., Voas, R. B., DuPont, R. L. & Shea, C. L. (2011). Smart justice for DWI offenders: Cost effective solutions that reduce recidivism and promote public safety. *Journal of Offender Monitoring*, 23(1), 9-12.
319. Voas, R. B., DuPont, R. L., Talpins, S. K. & Shea, C. L. (2011). Towards a national model for managing impaired driving offenders. *Addiction*, 106(7), 1221-1227.
320. DuPont, R. L. & Madras, B. K. (2011, Winter). Marijuana, schizophrenia and Jared Loughner. *DATIA Focus*, 4(1), 28-31.
321. DuPont, R. L., R. L., Goldberger, B. A. & Gold, M. S. (2011). Clinical and legal considerations in drug testing. In C. A. Cavacuiti (Ed.) *Principals of Addiction Medicine: The Essentials* (pp. 593-598). Philadelphia, PA: Lippincott Williams & Wilkins.
322. DuPont, R. L., Madras, B. K. & Johansson, P. (2011). Drug policy: A biological science perspective. In J. H. Lowinson & P. Ruiz (Eds.) *Substance Abuse: A Comprehensive Textbook* (5th ed., pp. 998-1010). Philadelphia, PA: Lippincott Williams & Wilkins.
323. DuPont, R. L. (2011). The many problems and consequences of marijuana use: Marijuana use is a serious threat to public health. *The Journal of Global Drug Policy and Practice*, 5(2).
324. Skipper, G. E. & DuPont, R. L. (2011). The advantages of long-term monitoring. *Addiction Professional*, 9(4), 44-48.
325. DuPont, R. L. & Selavka, C. M. (2011). Testing to identify recent drug use. In M. Galanter & H. D. Kleber (Eds.), *Psychotherapy for the Treatment of Substance Abuse* (1st ed., pp. 53-79). Washington, DC: American Psychiatric Publishing, Inc.
326. Buhl, A., Oreskovich, M. R., Meredith, C. W., Campbell, M. D. & DuPont, R. L. (2011). Prognosis for the recovery of surgeons from chemical dependency. *Archives of Surgery*, 146(11), 1286-1291.

327. Pike, G., Santamaria, J., Reece, S., DuPont, R., Mangham, C. & Christian, G. (2011). Analysis of the 2011 Lancet study on deaths from overdose in the vicinity of Vancouver's Insite Supervised Injection Facility. *Journal of Global Drug Policy and Practice*, 5(3).
328. DuPont, R. L. (2011). Using marijuana as medicine – A fresh look. *ASAM News*, 26(3), 5-6.
329. DuPont, R. L., Voas, R. B., Walsh, J. M., Shea, C., Talpins, S. K. & Neil, M. M. (2012). The need for drugged driving per se laws: A commentary. *Traffic Injury Prevention*, 13(1), 31-42.
330. DuPont, R. L., Martin, D. M. & Skipper, G. E. (2012). A new challenge for drug-free workplace programs. *Occupational Health and Safety*, 81(2).
331. Wish, E. D., Artigiani, E., Billing, A., Hauser, W., Hemberg, J., Shipton, M., DuPont, R. L. (2012). The emerging buprenorphine epidemic in the United States. *Journal of Addictive Diseases*, 31(1), 3-7.
332. DuPont, R. L. & Skipper, G. E. (2012). Six lessons from physician health programs to promote long-term recovery. *Journal of Psychoactive Drugs*, 44(1), 72-78.
333. DuPont, R. L. (2012). The global future of drug testing and demand reduction. *DATIA Focus*, 5(2), 28-31.
334. Reisfield, G. M., Goldberger, B. A., Gold, M. S. & DuPont, R. L. (2012). The mirage of impairing drug concentration thresholds: A rationale for zero tolerance *per se* driving under the influence of drugs laws. *Journal of Analytical Toxicology*, 36(5), 353-356.
335. Kleber, H. D. & DuPont, R. L. (2012). Physicians and medical marijuana. *American Journal of Psychiatry*, 169(6), 564-568.
336. Blumenthal, K., DuPont, R. L. & Gold, M. S. (2012). Treatment of alcohol and drug dependence in 2011 and relevance to food addiction. In K. D. Brownell & M. S. Gold (Eds.) *Food and Addiction: A Comprehensive Textbook* (pp. 318-328). New York, NY: Oxford University Press.
337. DuPont, R. L. (2012). Lessons from drug policy. In K. D. Brownell & M. S. Gold (Eds.) *Food and Addiction: A Comprehensive Textbook* (pp. 423-429). New York, NY: Oxford University Press.
338. DuPont, R. L. (2012). Läkemedelsassisterad behandling måste leda till långvarig drogfrihet [Drug-assisted therapy must lead to long-term abstinence]. *Svenska Narkotika Polisförningens Tidskrift*, 4(5), 22.
339. DuPont, R. L. (2012). Foreword. In J. Hartelius, *Nils Bejerot and the Great Swedish Drug Epidemic*. Stockholm, Sweden: Swedish Carnegie Institute and World Federation Against Drugs.

340. DuPont, R. L. (2012). Drug Control Policy, Office of National. In D. T. Critchlow & P. R. VanderMeer (Eds.) *The Encyclopedia of American Political and Legal History*. New York, NY: Oxford University Press.
341. Kleber, H. D. & DuPont, R. L. (2012). Response to Grant et al. letter. *American Journal of Psychiatry*, 169(10), 1120.
342. Morrison, R. A. & DuPont, R. L. (2013). The new paradigm and the DOT/SAP process. *Journal of Employee Assistance*, 43(1), 26-28.
343. DuPont, R. L., Campbell, M. D., Campbell, T. G., Shea, C. L. & DuPont, H. S. (2013). Self-reported drug and alcohol use and attitudes toward drug testing in high school with random student drug testing. *Journal of Child & Adolescent Substance Abuse*, 22(2), 104-119.
344. DuPont, R. L., Reisfield, G. M., Goldberger, B. A. & Gold, M. S. (2013). The seductive mirage of a 0.08 g/dL BAC equivalent for drugged driving. *DATIA Focus*, 6(1), 36-43.
345. Reisfield, G. M. & DuPont, R. L. (2013). Recommend against the medicinal use of marijuana [Clinical Decisions]. *New England Journal of Medicine*, 368(9), 886-868.
346. DuPont, R. L. (2013). An effective public health approach to reduce marijuana use. In D. Newton. (Ed). *Marijuana: A Reference Handbook* (pp. 136-139). Santa Barbara, CA: ABC-CLIO.
347. Reisfield, G. M., Shults, T., Demery, J. & DuPont, R. L. (2013). A protocol to evaluate drug-related workplace impairment. *Journal of Pain and Palliative Care Pharmacotherapy*, 27(1), 43-48.
348. DuPont, R. L., Merlo, L. J., Arria, A. M. & Shea, C. L. (2013). Random student drug testing as a school-based drug prevention strategy. *Addiction*, 108(5), 839-845.
349. DuPont, R. L., Merlo, L. J., Arria, A. M. & Shea, C. L. (2013). Response to commentaries on random student drug testing. *Addiction*, 108(5), 850-851.
350. Voas, R. B., DuPont, R. L., Shea, C. L. & Talpins, S. K. (2013). Prescription drugs, drugged driving and per se laws. *Injury Prevention*, 19(3), 218-221.
351. DuPont, R. L., Talpins, S. K. & Shea, C. L. (2013). Commentary on Romano & Pollini (2013): Stopping drug-impaired driving and alcohol-impaired driving—synergy, not competition. *Addiction*, 108(8), 1439-1440.
352. Skipper, G. E., Thon, N., DuPont, R. L., Baxter, L. & Wurst, F. M. (2013). Phosphatidylethanol: the potential role in further evaluating low positive urinary ethyl glucuronide and ethyl sulfate results. *Alcoholism, Clinical and Experimental Research*, 37(9), 1582-1586.

353. DuPont, R. L. (2013). Marijuana legalization and federal law: a missed opportunity. *Journal of Global Drug Policy and Practice*, 7(3).
354. White, W. L., Campbell, M. D., Shea, C., Hoffman, H. A., Crissman, B. & DuPont, R. L. (2013). Coparticipation in 12-step mutual aid groups and methadone maintenance treatment: a survey of 322 patients. *Journal of Groups in Addiction & Recovery*, 8(4), 294-308.
355. Skipper, G. E., Thon, N., DuPont, R. L., Campbell, M. D., Weinmann, W. & Wurst, F. M. (2014). Cellular photo digital for monitoring alcohol use: a pilot study. *European Addiction Research*, 20(3), 137-142.
356. White, W. L., Campbell, M. D., Spencer, R. A., Hoffman, H. A., Crissman, B. & DuPont, R. L. (2014). Participation in Narcotics Anonymous and Alcoholics Anonymous and abstinence outcomes of 322 methadone maintenance patients. *Journal of Groups in Addiction & Recovery*, 9(1), 14-30.
357. Talpins, S. K., DuPont, R. L., Voas, R. B., Holmes, E., Sabet, K. A. & Shea, C. L. (2014). License revocation as a tool for combating drugged driving. *Impaired Driving Update*, 18(2).
358. White, W. L., Campbell, M. D., Spencer, R. D., Hoffman, H. A., Crissman, B. & DuPont, R. L. (2014). Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. *Journal of Psychoactive Drugs*, 46(2), 114-122.
359. DuPont, R. L. & Coleman, J. J. (2014). Drug control policy: history and future directions. In R. K. Ries, D. A. Fiellin, S. C. Miller & R. Saitz (Eds.), *Principles of Addiction Medicine* (5th ed., pp. 1711-1714). Philadelphia, PA: Wolters Kluwer.
360. DuPont, R. L., Goldberger, B. A. & Gold, M.S. (2014). The science and clinical uses of drug testing. In R. K. Ries, D. A. Fiellin, S. C. Miller & R. Saitz (Eds.), *Principles of Addiction Medicine* (5th ed., pp. 1717-1728). Philadelphia, PA: Wolters Kluwer.
361. DuPont, R. L., Ferguson, J. L. (2014). Workplace drug testing and the role of the medical review officer. In R. K. Ries, D. A. Fiellin, S. C. Miller & R. Saitz (Eds.), *Principles of Addiction Medicine* (5th ed., pp. 1725). Philadelphia, PA: Wolters Kluwer.
362. Yellowlees, P. M., Campbell, M. D., Rose, J. S., Parish, M. B., Ferrer, D., Scher, L. M., Skipper, G. E. & DuPont, R. L. (2014). Psychiatrists with substance use disorders: positive treatment outcomes from physician health programs. *Psychiatric Services*, 65(12), 1492-1495.
363. DuPont, R. L. & Shea, C. L. (2014, August). The public safety threat of drugged driving. *Need to Know*. Alexandria, VA: National Association of Drug Court Professionals.
364. DuPont, R. L. & Selavka, C. M. (2015). Testing to identify recent drug use. In M. Galanter, H. D. Kleber & K. T. Brady (Eds.), *Textbook of Substance Abuse Treatment* (5th ed., pp. 741-755). Arlington, VA: American Psychiatric Publishing, Inc.

365. DuPont, R. L. (2015). While the US Zigs on Pot, the Netherlands Zags. *The Journal of Global Drug Policy and Practice*, 9(1).
366. Talpins, S. K., DuPont, R. L., Walls, C. H., Sabet, K., & Wallace, D. (2015). The Miami-Dade protocol: making drugged driving enforcement a reality. *Journal of Alcohol and Drug Dependence*, 3(4), 212-213.
367. Braquehais, M. D., Tresidder, A. & DuPont, R. L., (2015). Service provision to physicians with mental health and addiction problems. *Current Opinion in Psychiatry*, 28(4), 324-329.
368. DuPont, R. L., Compton, W. M. & McLellan, A. T. (2015). Five-year recovery: A new standard for assessing effectiveness of substance use disorder treatment. *Journal of Substance Abuse Treatment*, 58, 1-5.
369. DuPont, R. L. (2015, Fall). Drug testing and legal marijuana: What should contractors do? *The Construction User*, 14-15, 23.
370. Angres, D., DuPont, R. & Gold, M. S. (2015). Perspectives on the opioid crisis. *Psychiatric Annals*, 45(10), 522-526.
371. Walsh, J. M. & DuPont, R. L. (2015, Fall). DUI: It's not just alcohol. Partnership for a Drug-Free New Jersey. *Drugs Don't Work in NJ Update*, 76.
372. DuPont, R. L. (2015, November 24). Rising death rates of white midlife Americans. *Clinical Psychiatry News*.
373. Alm, S., Inouye, C. E. & DuPont, R. L. (2015, December 1). The HOPE strategy: procedural justice in action. *National Partnership on Alcohol Misuse and Crime (NPAMC) Blog*.
374. DuPont, R. L., Seppala, M. D. & White, W. L. (2015). The three missing elements in the treatment of substance use disorders: lessons from the physician health programs. *Journal of Addictive Diseases*, 35(1), 3-7.
375. DuPont, R. L. (2015). The global drug problem: an introduction. In *Drug Policy Futures, Future of Drug Policy: Real Solutions Grounded in Global Evidence* (pp. 7-9). Stockholm, Sweden: Drug Policy Futures.
376. Campbell, M. D., Kolodner, G., Spencer, R. A. & DuPont, R. L. (2016). Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program. *Journal of Addictive Diseases*, 35(4), 315-324.
377. Finlayson, A. J. R., Iannelli, R. J., Brown, K. P., Neufeld, R. E., DuPont, R. L., & Campbell, M. D. (2016). Physician suicide and physician health programs. *General Hospital Psychiatry*, 40, 84-85.

378. DuPont, R. L. (2016). An outsider looks at PHP care management. *Physician Health News*, 21, 7-8.
379. Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L., & DuPont, R. L. (2016). Outcomes for physicians with opioid dependence treated without agonist pharmacotherapy in physician health programs. *Journal of Substance Abuse Treatment*, 64, 47-54.
380. DuPont, R. L. (2016). Seizing the moment to improve addiction treatment. *ASAM Magazine*.
381. DuPont, R. L. (2016). Getting serious about substance abuse treatment requires adopting the five-year recovery standard. *Journal of Global Drug Policy and Practice*, 10(3).
382. Merlo, L. J., & DuPont, R. L. (2016). Essential components of physician health program participation: perspectives of participants five years post-graduation. *Physician Health News*, 1, 14-15.
383. DuPont, R. L., Garcia-Rosales, K., Shea, C. L., DuPont, H., Campbell, M. D., Kolodner, G., & Wish, E. (2017). Are prescription opioids creating a new type of heroin user? *The Journal of Global Drug Policy and Practice*, 11(1).
384. DuPont, R. L. (2017). An effective public health approach to reduce marijuana use. In D. Newton. (Ed). *Marijuana: A Reference Handbook* (2nd ed., pp. 141-146). Santa Barbara, CA: ABC-CLIO.
385. DuPont, R. L. (2017). The opioid epidemic is an historic opportunity to improve both prevention and treatment. *Brain Research Bulletin*, S0361-9230(17), 30292-30297.
386. Carr, G. D., Hall, B., Finlayson, A. J. R., & DuPont, R. L. (2017). Physician health programs: the US model. In K. J. Brower & M. B. Riba (Eds.), *Physician Mental Health and Well-Being: Integrating Psychiatry and Primary Care* (pp. 265-294). Cham, Switzerland: Springer International Publishing.
387. DuPont, R. L. (2017, July/August). New trends in workforce drug use. *Risk Management*, 14-15.
388. Han, B., Compton, W. M., Blanco, C., & DuPont, R. L. (2017). National trends in substance use and use disorders among youth. *Journal of the American Academy of Child & Adolescent Psychiatry*, 56(9), 747-754.
389. a. DuPont, R. L. (2018). A new narrative to understand the opioid epidemic. *The Journal of Global Drug Policy and Practice*, 12(1).
- b. DuPont, R. L. (2018, Winter). A new narrative to understand the opioid epidemic. *DATIA Focus*, 11(1), 6-13.
390. DuPont, R. L., & Merlo, L. J. (2018). Physician health programs: a model for treating substance use disorders. *The Judges' Journal*, 57(1), 32-35.

391. DuPont, R. L., Han, B., Shea, C. L., & Madras, B. K. (2018). Drug use among youth: national survey data support a common liability of all drug use. *Preventive Medicine, 113*, 68-73.

BOOK & JOURNAL REVIEWS

1. DuPont, R. L. (1973). [Review of the books *Licit and Illicit Drugs* and *Guide to Drug Rehabilitation: A Public Health Approach*]. *Psychiatry, 36*, 351.
2. DuPont, R. L. (1973). The methadone issue. [Review of the book *Methadone: Experiences and Issues*]. *Federal Probation, 37*(4), 82.
3. DuPont, R. L. (1975). [Review of the book *Narcotic Antagonists*]. *Journal of Nervous and Mental Disease, 160*(1), 57.
4. DuPont, R. L. & Ginzburg, H. M. (1976). The confusing state of drug abuse evaluation. [Review of the books *The Effectiveness of Drug Abuse Treatment: Evaluation of Treatments* and *The Effectiveness of Drug Abuse Treatment: Research on Patient, Treatment, and Outcomes*]. *Contemporary Psychology, 21*(7), 500-501.
5. DuPont, R. L. (1991). Nicotine dependence. [Review of the book *The Clinical Management of Nicotine Dependence*]. *Journal of the American Medical Association, 266*, 3202-3203.
6. DuPont, R. L. (1992). [Review of the book *The Nature of Drug Dependence*]. *Journal of Studies on Alcohol, 53*, 395-396.
7. DuPont, R. L. (1993). Drunk driving. [Review of the book *Confronting Drunk Driving: Social Policy for Saving Lives*]. *Journal of the American Medical Association, 270*, 100.
8. DuPont, R. L. (1994). [Review of the book *Nicotine Addiction: Principles and Management*]. *Journal of the American Medical Association, 272*, 1221.
9. DuPont, R. L. (1995). [Review of the book *Marihuana: The Forbidden Medicine*]. *Journal of Nervous and Mental Disease, 183*, 668-669.
10. DuPont, R. L. (1996). Tobacco. [Review of the book *Tobacco*]. *Journal of the American Medical Association, 275*, 1285.
11. DuPont, R. L. (1997). [Review of the book *Tobacco*]. *Journal of the American Medical Association, 275*, 1285.
12. DuPont, R. L. (1997). [Review of the book *Drug Abuse and Social Policy in America: The War that Must be Won*]. *Journal of Nervous and Mental Disease, 185*, 354.

13. DuPont, R. L. (1999). Comments on "Reasons to Worry About the Environment." *Cosmos 1998: Journal of the Cosmos Club of Washington, DC*, 8, 16-17.
14. DuPont, R. L. (1999). [Review of the book *The Secret Strength of Angels: 7 Virtues to Live By*]. *American Journal of Psychiatry*, 156, 12.
15. DuPont, R. L. (2000). [Review of the book *Faith, Healing and Miracles*]. Long Island City, NY: *The Hatherleigh Company*.
16. DuPont, R. L. (2000). [Review of the book *Alcohol and the Community: A Systems Approach to Prevention*]. *Bulletin of the Menninger Clinic*, 64(1), 13-15.
17. DuPont, R. L. (2000). [Review of the book *Dangerous Drugs*]. Center City, MN: Hazelden.
18. DuPont, R. L. (2000). [Review of the book *Save My Son: A Mother and a Sheriff Unite to Save the Lives of Addicted Offenders*]. Center City, MN: Hazelden.
19. DuPont, R. L. (2000). [Review of the book *Addiction Treatment: Avoiding Pitfalls: A Case Approach*]. *Bulletin of the Menninger Clinic*, 64(3), 1-2.
20. DuPont, R. L. (2001). [Review of the book *Changing Addictive Behavior*]. *Bulletin of the Menninger Clinic*, 65(2), 297-299.
21. DuPont, R. L. (2001). [Review of the book *The Healing Power of Faith: Science Explores Medicine's Last Great Frontier*]. *American Journal of Psychiatry*, 158(8), 1347-1348.
22. DuPont, R. L. (2002). [Review of the book *Forces of Habit: Drugs and the Making of the Modern World*]. *Journal of Nervous and Mental Disease*, 190(4), 270.
23. DuPont, R. L. (2002). [Review of the book *The Wounded Healer: Addiction-Sensitive Approach to the Sexually Exploitative Professional*]. *Bulletin of the Menninger Clinic*, 66(1), 92-94.
24. DuPont, R. L. (2003). Addiction policy. [Review of the book *Creating the American Junkie: Addiction Research in the Classic Era of Narcotic Control*]. *Journal of the American Medical Association*, 289(17), 2286-2287.
25. DuPont, R. L. (2003). Thinking outside the urine cup. [Review of the article *Urine Testing in Methadone Treatment: Applications and Limitations*]. *Journal of Substance Abuse Treatment*, 25, 67-68.
26. DuPont, R. L. (2004). [Review of the book *Eating Disorders, Overeating, and Pathological Attachment to Food: Independent or Addictive Disorders*]. Binghamton, NY: Haworth Medical.
27. DuPont, R. L. (2004). [Review of the book *The Treatment of Anxiety Disorders: Clinician Guides and Patient Manuals*, 2nd ed. and *The Anxiety Book: Developing Strength in the Face of*

Fear]. *American Journal of Psychiatry*, 161(5), 940-941.

28. DuPont, R. L. (2006). Substance abuse journal [Review of the article *Methamphetamine Use Among Treatment Seeking Youth: An Emerging Problem?*]. Providence, RI: Brown University.

LETTERS TO THE EDITOR

1. DuPont, R. L. (1972, November 30). The DC heroin epidemic: Progress report [Letter to the editor]. *New England Journal of Medicine*, 1154.
2. DuPont, R. L. (1974). Epidemic [Letter to the editor]. *Journal of the American Medical Association*, 227(12), 1380.
3. DuPont, R. L. (1987, Summer). Drug abuse [Letter to the editor]. *Issues in Science and Technology*, 10.
4. DuPont, R. L. (1988, April 30). Drugs [Letter to the editor]. *The Economist*, 4-6.
5. DuPont, R. L. (1989, October 15). Why don't drug legalizers have a plan? [Letter to the editor]. *The Washington Post*, p. B6.
6. DuPont, R. L. & Saylor, K. E. (1989). Marijuana and benzodiazepines in patients receiving methadone treatment [Letter to the editor]. *Journal of the American Medical Association*, 261, 3409.
7. DuPont, R. L. & Bogema, S. C. (1990). Benzodiazepines in a health-catalog product [Letter to the editor]. *Journal of the American Medical Association*, 264, 695.
8. DuPont, R. L. & Haley, R. G. (1991). Drug testing for prescribed medicines [Letter to the editor]. *Substance Abuse*, 12, 65-66.
9. Saylor, K. E., DuPont, R. L. & Brown, H. (1992). The high way: Driving under influences other than alcohol [Letter to the editor]. *Journal of the American Medical Association*, 267, 652.
10. DuPont, R. L. (1993, Spring). The black pearl of China [Letter to the editor]. *Priorities*, 3.
11. DuPont, R. L. (1994). The war on drugs: A peace proposal [Letter to the editor]. *New England Journal of Medicine*, 331(2), 128.
12. DuPont, R. L. (1997). Medicinal marijuana? [Letter to the editor]. *New England Journal of Medicine*, 336(16), 1184.
13. Kessler, R. C., DuPont, R. L., Wittchen, H. U. & Berglund, P. A. (2000). Impairment in Generalized Anxiety Disorder [Letter to the editor]. *American Journal of Psychiatry*, 157, 2060-

2061.

14. DuPont, R. L. (2000, December 2). Don't abandon parole reform [Letter to the editor]. *The Sun*, p. 19A.
15. DuPont, R. L. (2005, June 2). Smoked marijuana is not medicine [Letter to the editor]. *The Washington Times*.
16. DuPont, R. L., Gold, M. S. & Graham, N. A. (2007, January 24). Opioid prescriptions for back pain and iatrogenic addictions [Letter to the editor]. *Annals of Internal Medicine*.
17. Graham, N. A., DuPont, R. L. & Gold, M. S. (2007, June). Symptoms of ADHD or marijuana use? [Letter to the editor]. *American Journal of Psychiatry*.
18. DuPont, R. L., Graham, N. A. & Gold, M. S. (2007, September 4). Opioid treatment for chronic back pain and its association with addiction [Letter to the editor]. *Annals of Internal Medicine*, 147(5), 348-349.
19. DuPont, R. L., Skipper, G. E. (2009, January 8). Correspondence: What about physician health programs? [Letter to the editor]. *The New Republic*.
20. DuPont, R. L. (2010, April 25). Medical marijuana is a big step toward legalizing pot [Letter to the editor]. *The Washington Post*, p. A20.
21. DuPont, R. L. (2010, August 3). The side effects of Arizona's immigration law. [Letter to the editor]. *The Washington Post*, p. A14.
22. DuPont, R. L. (2011, July 9). Zero tolerance behind the wheel. [Letter to the editor]. *Los Angeles Times*.
23. DuPont, R. L. (2011, August 15). Another view: Medical marijuana bad medicine and bad public policy [Letter to the editor]. *The Portland Press Herald*.
24. DuPont, R. L. (2011, October 15). Testing state aid recipients for drugs. [Letter to the editor]. *The New York Times*, p. A18.
25. DuPont, R. L. (2011, December). Overcoming nuclear fear. [Letter to the editor]. *Public Utilities Fortnightly*, 149(12), p. 10.
26. DuPont, R. L. (2012, January 16). Marijuana study flawed. [Letter to the editor]. *The Washington Times*.
27. Bensinger, P. B., DuPont, R. L. (2012, February 23). Taxing medical marijuana. [Letter to the editor]. *The New York Times*.

28. Bensinger, P. B. & DuPont, R. L. (2012, April 1). The DEA's prescription drug policy saves many lives. [Letter to the editor]. *The Wall Street Journal*.
29. DuPont, R. L. & Bensinger, P. B. (2012, December 2). Recklessly commercializing pot. [Letter to the editor]. *The Washington Post*.
30. DuPont, R. L., Bensinger, P. B. & Blue, L. (2013, January 15). Can drug legalization end the destruction of lives? [Letter to the editor]. *The Wall Street Journal*.
31. Bensinger, P. & DuPont, R. L. (2014, August 1). Legalizing marijuana: pros and cons. *New York Times*, p. A22.
32. DuPont, R. L. (2016, August 5). The deadliness of heroin and tobacco easily underestimated. *The Washington Post*.
33. DuPont, R. L. (2017, April 9). Another risk factor in middle-age deaths. *The Washington Post*.
34. DuPont, R. L. (2017, September 4). No good DUI impairment test for marijuana is likely. *The Wall Street Journal*.

OPPOSITE EDITORIALS, DEBATE & COMMENTARIES

1. DuPont, R. L. (1976, December 4). Pot: Mild intoxicant, or serious menace? [Debate and discussion]. *The Sun*.
2. DuPont, R. L. (1980, July 20). Phobic fear as a nuclear health hazard [Comment]. *The Washington Star*.
3. DuPont, R. L. (1986, July 18). Dear Abby. *The Montgomery Journal*, p. C16.
4. DuPont, R. L. (1986). Should all doctors be tested for illegal drug use? [Point/Counterpoint]. *Physicians Weekly*, 3(32).
5. DuPont, R. L. (1986, February). Should drug testing in the workplace be mandatory? [Point/Counterpoint]. *The U. S. Journal*, 10.
6. DuPont, R. L. (1986, September 9). We can beat the product-tampering threat. *The Washington Post* [Health Section], 6.
7. DuPont, R. L. (1987, Summer). Zero tolerance. *Issues in Science and Technology*, 10.
8. DuPont, R. L. (1988, April 19). Is random mandatory drug testing needed? *The Washington Post* [Health Section], 8; also published 1988 in *Physicians Weekly*, 4(4).

9. DuPont, R. L. (1989, March 14). Workplace urine tests will cut drug use [Viewpoints]. *Newsday*, 65.
10. DuPont, R. L. (1992, Winter). A clinician's boundaries for social drinking: When to say when to alcohol [Point/Counterpoint]. *Priorities*, 17-19.
11. London, W. & DuPont, R. L. (1995). Will legalizing drugs benefit public health? [Point/Counterpoint]. *Priorities*, 7(2), 24-30.
12. DuPont, R. L. & Bennett, W. J. (2001, March 5). Advice for the next drug czar [Op-Ed]. *The Miami Herald*, p. 7B.
13. DuPont, R. L. (2003, September 22). Marijuana: Why it's America's most dangerous drug [Viewpoint]. *The Montgomery Journal*, p. 7.
14. DuPont, R. L. & Walsh, J. M. (2007, June 17). The drugged driving epidemic: Why the mayhem at a southeast festival wasn't the fluke you might think it was [Op-Ed]. *The Washington Post*, p. B8.
15. Gold, M. S. & DuPont, R. L. (2008). Teens + marijuana: Still a dangerous mix [Guest Editorial]. *Clinical Psychiatry News*, 36(7), 14.
16. DuPont, R. L. (2009). Barack Obama on medical marijuana [Commentary]. *The Journal of Global Drug Policy and Practice*, 3(1).
17. Arria, A. M. & DuPont, R.L. (2009). Let's end nonmedical use of stimulants [Editorial]. *Family Psychiatry News*, 39(17), 29.
18. Arria, A. M. & DuPont, R.L. (2009). Nonmedical use of stimulants must stop [Editorial]. *Clinical Psychiatry News*, 37(12), 6.
19. DuPont, R. L. & Carlsson, S-O. (2011, October 4). Sverige motgift mot harm-reduction [Sweden's antidote to harm-reduction] [Debate]. *DrugNews*.
20. DuPont, R. L. (2012, February 3). A new paradigm for substance abuse treatment [Commentary]. *Join Together and Partnership at Drugfree.org*.
21. DuPont, R. L. (2012, March). Should marijuana be legal? [Informed Debate]. *The Costco Connection*, 27(3), 14-15.
22. DuPont, R. L., Käll, K. & Johansson, P. (2012, August 30). Att knarka är ingen mänsklig rättighet [To take drugs is no human right] [Op-Ed]. *Svenska Dagbladet*.
23. DuPont, R. L. & Barthwell, A. (2012, September 4). Is marijuana addictive? [Debate]. *Huffington Post*.

24. DuPont, R. L., Käll, K. & Johansson, P. (2012, September 12). Se inte ungas missbruk som “normalt” [Do not view youth drug abuse as “normal”] [Op-Ed]. *Svenska Dagbladet*.
25. DuPont, R. L. (2012, September 24). LAB-behandling ska leda till drogfrihet [Drug-assisted maintenance treatment leads to abstinence] [Debate]. *DrugNews*.
26. DuPont, R. L. & Barthwell, A. (2012, October 1). Don't legalize marijuana. It's addictive [Op-Ed]. *Seattle Times*.
27. DuPont, R. L. (2012, December 20). Seizing the drug policy initiative [Commentary]. *Drugnews*.
28. DuPont, R. L. (2013, May 16). Lessons from Boston bombings about marijuana, education [Commentary]. *San Diego Union-Tribune*.
29. DuPont, R. L. (2013, September 5). Marijuana legalization wrong way to end war on drugs [Commentary]. *San Diego Union-Tribune*.
30. DuPont, R. L. (2013, October 24). The substance use-dropout connection [Blog]. *Shatterproof*.
31. DuPont, R. L. (2013, November 1). Leveraging justice system to reduce drug use [Commentary]. *San Diego Union-Tribune*.
32. DuPont, R. L., Madras, B. & Johansson, P. (2013, November 20). US needs to follow Sweden's lead in drug policy. *DrugNews*.
33. a. DuPont, R. L. (2013, December 16). Pitfalls of legalization? [Op-ed]. *The Mark News*.
 - b. DuPont, R. L. (2013, December 17). International analysis: The pitfalls of legalization? [Op-ed]. *Andean Air Mail & Peruvian Times*.
 - c. DuPont, R. L. (2013, December 18). The pitfalls of marijuana legalization [Analysis]. *Buenos Aires Herald*.
 - d. DuPont, R. L. (2013, December 18). The dangers of cannabis legalization [Comment]. *Cyprus Mail*.
 - e. DuPont, R. L. (2013, December 20). Drug legalization threatens public health and safety [Commentary]. *The Daily Star*, p.7.
34. DuPont, R. L. & Gold, M.S. (2014, January 28). Drugs wreaking havoc on our roads [Current Perspectives]. *American Association of Pharmaceutical Scientists (AAPS) Blog*.
35. DuPont, R. L. (2014, March 28). Alcoholics Anonymous, the 12-step fellowship: a modern miracle [Op-ed]. *Live Science*.

36. DuPont, R. L. & Lieberman, J. A. (2014, April 18). Marijuana legalization and young brains: time for a serious study [From the President]. *Psychiatric News*, 49(8), 1.
37. DuPont, R. L. & Lieberman, J. A. (2014, May 9). Young brains on drugs [Editorial]. *Science*, 344(6184), 557.
38. DuPont, R. L. (2014, August 28). The changing state of drug policy [Blog]. *Parents Opposed to Pot*.
39. DuPont, R. L. (2014, August 29). Pot is becoming legal in more places, but we should drug test employees anyway [PostEverything]. *The Washington Post*.
40. DuPont, R. L. (2015, March 5). Marijuana is addictive [Current Perspectives]. *American Association of Pharmaceutical Scientists (AAPS) Blog*.
41. DuPont, R. L. (2015, November 11). Drug addiction recovery often starts with coercion [Room for Debate]. *The New York Times*.
42. DuPont, R. L. (2015, December 13). Setting a new standard for treatment with five-year recovery. *ASAM Magazine*.
43. DuPont, R., Bensinger, P., & Blue, L. (2015, December 18). Lessons from pot experiment. *Colorado Springs Gazette*.
44. DuPont, R. L. (2016, April 26). Marijuana has proven to be a gateway drug [Room for Debate]. *The New York Times*.
45. DuPont, R. L. (2016, Spring/Summer). Drug abuse prevention should be about health: no use of alcohol, nicotine, marijuana and other drugs for reasons of health. [Voices from the Field]. *CADCA Coalitions*, 24(1), 9.
46. DuPont, R. L. (2016, August 25). Should patients with cancer be offered cannabis as a pain management strategy? [Point/Counter]. *HemOnc Today*.
47. DuPont, R. L. (2016, September 12). Benzodiazepines and addiction: new thinking about old drugs. *Kolmac Outpatient Recovery Centers Blog*.
48. DuPont, R. L. (2017, March/April). "Should patients with substance use disorders be prescribed benzodiazepines?" No. [Commentary] *Journal of Addiction Medicine*, 11(2), 84-86.
49. Bennett, W., & DuPont, R. L. (2017, June 29). Getting the opioid epidemic right. *The Daily Signal*.
50. Levy, S., DuPont, R. L., Fishman, M. J., & Hadland, S. (2017, September 28). Teen substance use declining, but addiction persists. *Thrive Global*.

51. DuPont, R. L. (2018). For a healthy brain teens make “one choice” [Commentary]. *The Journal of Global Drug Policy and Practice*, 12(1).

BIOGRAPHICAL INTERVIEWS

1. Brown, B.S. (2005). Conversation with Robert L. DuPont. *Addiction*, 100, 1402-1411.
2. White, W. L. (2010). Robert L. DuPont, M.D. on addiction, treatment recovery and a life of service. *Counselor*, 11(1), 38-48.

ORGANIZATION REPORTS & WHITE PAPERS

1. DuPont, R. L., for the Advisory Committee on Non-Medical Use of Prescription Stimulants. (2005). *Non-Medical Use of Methylphenidate: Defining the Problem, Creating Solutions*. Rockville, MD: Institute for Behavior and Health, Inc.
2. DuPont, R. L., for the Advisory Committee on Non-Medical use of Prescription Stimulants. (2005). *OROS® Methylphenidate Risk Assessment Program*. Rockville, MD: Institute for Behavior and Health, Inc.
3. DuPont, R. L. & Bucher, R. H. (2005). *Guide to Responsible Family Drug and Alcohol Testing*. Rockville, MD: Institute for Behavior and Health, Inc.
4. DuPont, R. L. & Graves, H. (2005). *Smarter Student Drug Testing*. Rockville, MD: Institute for Behavior and Health, Inc.
5. DuPont, R. L., Logan, B. K., Shea, C. L., Talpins, S. K. & Voas, R. B. (2011). *Drugged Driving: A White Paper*. Institute for Behavior and Health Drugged Driving Committee. Rockville, MD: Institute for Behavior and Health, Inc.
6. DuPont, R.L. & Bucher, R.H. (2012). *Guide to Responsible Family Drug and Alcohol Testing*. Rockville, MD: Institute for Behavior and Health, Inc.
7. DuPont, R. L., Caldeira, K. M., DuPont, H. S., Vincent, K. B., Shea, C. L. & Arria, A. (2013). *America’s Dropout Crisis: The Unrecognized Connection to Adolescent Substance Use*. Rockville, MD: Institute for Behavior and Health, Inc.
8. Institute for Behavior and Health, Inc. (2014). *The New Paradigm for Recovery: Making Recovery – and Not Relapse – the Expected Outcome of Addiction Treatment*. Rockville, MD: Author.
9. Institute for Behavior and Health, Inc. (2014). *Creating a New Standard for Addiction Treatment Outcomes*. Rockville, MD: Author.

10. Institute for Behavior and Health, Inc. (2015). *Workplace Drug Testing in the Era of Legal Marijuana*. Rockville, MD: Author.
11. Institute for Behavior and Health, Inc. (2015). *State of the Art of HOPE Probation*. Rockville, MD: Author.
12. Institute for Behavior and Health, Inc. (2015). *HOPE-Like Probation and Parole: 2015 Survey Summary*. Rockville, MD: Author.
13. Institute for Behavior and Health, Inc. (2015). *The HOPE Probation Strategy and Fidelity to It: A Summary*. Rockville, MD: Author.
14. Institute for Behavior and Health, Inc. (2016). *A Strategy to Assess the Consequences of Marijuana Legalization*. Rockville, MD: Author.
15. DuPont, R. L., & McLellan, A. T. (2017). “Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drug Abuse and Health”: A New Agenda to Turn Back the Drug Epidemic. Rockville, MD: Institute for Behavior and Health, Inc.
16. Larkin, P. J., DuPont, R. L., & Madras, B. K. (2018, May 16). *The Need to Treat Driving Under the Influence of Drugs as Seriously as Driving Under the Influence of Alcohol*. Backgrounder, 3316. Washington, DC: The Heritage Foundation.

JOURNAL PEER-REVIEW

- | | |
|--|--|
| - <i>Addiction</i> | - <i>JAMA: Journal of the American Medical Association</i> |
| - <i>American Journal of Psychiatry</i> | - <i>JAMA Psychiatry</i> |
| - <i>American Journal of Preventive Medicine</i> | - <i>Journal of Addiction Medicine</i> |
| - <i>Annals of Internal Medicine</i> | - <i>Journal of Clinical Psychiatry</i> |
| - <i>BMJ Open</i> | - <i>Journal of Drug Policy Analysis</i> |
| - <i>BMJ Quality & Safety</i> | - <i>Journal of Global Drug Policy and Practice</i> |
| - <i>Clinical Chemistry</i> | - <i>Journal of Psychoactive Drugs</i> |
| - <i>Drug and Alcohol Dependence</i> | - <i>Journal of Studies on Alcohol and Drugs</i> |
| - <i>Drug and Alcohol Review</i> | - <i>Journal of Substance Abuse Treatment</i> |
| - <i>Drugs: Education, Prevention & Policy</i> | - <i>New England Journal of Medicine</i> |
| - <i>Expert Opinion on Drug Delivery</i> | - <i>Pediatrics</i> |
| - <i>Expert Review of Vaccines</i> | - <i>Pediatrics</i> |
| - <i>Injury Epidemiology</i> | - <i>Substance Use and Misuse</i> |
| - <i>Injury Prevention</i> | - <i>Therapeutic Advances in Drug Safety</i> |
| - <i>International Perspectives in Psychology</i> | |